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1 Summary 
The steroid hormone aldosterone plays a crucial role in cardiovascular disease as demonstrated 
by the fact that antagonism of the mineralocorticoid receptor (MR), which is the receptor of 
aldosterone, decreases atherosclerosis by reducing inflammation and oxidative stress. Obesity is 
a chronic inflammatory disease that is associated with the development of endothelial 
dysfunction, the initial step in the development of atherosclerosis. Interestingly, obesity is 
characterized by increased plasma aldosterone levels. 
The aim of this thesis was to characterize the role of aldosterone and the endothelial MR 
signaling in the development of obesity-induced endothelial dysfunction. 
To study the role of endogenous aldosterone in this context, we exposed 6-weeks old male 
C57BL/6 mice to a normal chow or a high-fat diet (60% lard). The high-fat diet was administered 
alone or in combination with the MR antagonist eplerenone (200mg/kg/day). After 14 weeks of 
diet, obesity-induced impaired glucose tolerance, white adipose tissue inflammation and 
endothelial dysfunction were attenuated by eplerenone. Analyses of freshly isolated aortic 
endothelial cell mRNA revealed that eplerenone administration regulates beneficially obesity-
induced expression of oxidative stress-modulating genes such as NADPH oxidase subunits 
p22phox and p40phox as well as superoxide dismutase (SOD)-1 and-3. Interestingly, eplerenone 
did not alter the mRNA expression of cyclooxygenases-1 (COX-1) and prostacyclin synthase that 
produce vasoconstricting prostanoids in obesity. To investigate the role of endothelial MR, we 
exposed endothelial-selective MR knockout (EC MR KO) mice to a high-fat diet or infused them 
with exogenous aldosterone (50μg/kg/d). Obesity- as well as aldosterone-induced endothelial 
dysfunction was entirely prevented by endothelial MR ablation. A similar protection was 
observed by COX inhibition with indomethacin, underlining the importance of increased 
endothelial COX-1 and prostacyclin synthase expression in obesity. Experiments with 
aldosterone-treated EC MR KO mice revealed that aldosterone induces expression of 
prostacyclin synthase mRNA in an endothelial MR-independent manner in aortic endothelial 
cells. We suggest that this increase in prostanoid-producing enzyme by aldosterone contributes 
critically to obesity-induced endothelial dysfunction. In addition, aldosterone modulates the 
expression of p22phox and SOD-1 in an endothelial MR-dependent manner. These aldosterone 
and endothelial MR-mediated changes related to oxidative stress might be the key events 
leading to obesity-induced endothelial dysfunction.  
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We show that genetic loss-of-function of the endothelial MR tips the balance to anti-oxidative 
side in aortic endothelial cells, resulting in attenuated endothelial dysfunction in obesity and 
conclude that the endothelial MR plays a crucial role in obesity-induced endothelial dysfunction. 
 
2 Zusammenfassung 
 
 
- 9 - 
 
2 Zusammenfassung 
Das Steroidhormon Aldosteron spielt eine essentielle Rolle bei der Entstehung kardiovaskulärer 
Erkrankungen und aktiviert durch seine Bindung den Mineralokortikoidrezeptor (MR). 
Antagonismus des MR vermindert die Entwicklung von Arteriosklerose durch Reduktion von 
Endzündungen und oxidativem Stress. Fettleibigkeit ist ein chronisch entzündlicher Zustand, der 
mit der Entstehung von endothelialer Dysfunktion, dem initialen Schritt in der Entwicklung von 
Arteriosklerose, assoziiert wird. Interessanterweise sind erhöhte Plasma-Aldosteron-Werte 
charakteristisch für Fettleibigkeit. 
Das Ziel dieser Doktorarbeit war es, die Effekte von Aldosteron und endothelialer MR 
Aktivierung bei der Entstehung von Fettleibigkeits-assoziierter endothelialer Dysfunktion zu 
analysieren. 
Um die Rolle von endogenem Aldosterone in diesem Kontext zu untersuchen, haben wir sechs 
Wochen alte männliche C57BL/6 auf eine normale Diät und eine Fett-Diät gesetzt. Die Fett-Diät 
wurde mit und ohne MR Antagonist Eplerenon (200mg/kg/Tag) verabreicht. Nach 14 Wochen 
Diät wurde sowohl die Adipositas induzierte verschlechterte Glukose Toleranz,  sowie die 
Entzündung im weißen Fettgewebe, als auch die endotheliale Dysfunktion durch Verabreichung 
des Eplerenons vermindert. Die Analyse frisch isolierter Aorten-Endothelzellen-mRNA zeigte, 
dass sich eine Verabreichung von Eplerenon vorteilhaft auf die Expression von Enzymen 
auswirkt, die mit Adipositas assoziiert sind und oxidativen Stress modulieren. Dazu gehören die 
NADPH-Oxidase-Untereinheiten p22phox und p40phox, aber auch Superoxiddismutase (SOD) 1 
und 3. Interessanterweise beeinflusst Eplerenon nicht die Expression von Cyclooxygenase (COX-
1) und Prostacyclin-Synthase, welche bei Fettleibigkeit gefässverengende Prostanoide 
produzieren. Um die Rolle des endothelialen MR zu untersuchen, haben wir endothelspezifische 
MR Knock-Out-Mäuse (EC MR KO) auf eine Fett-Diät gesetzt oder sie zwei Wochen lang mit 
exogenem Aldosterone (50μg/kg/Tag) behandelt. Fettleibigkeit- und Aldosteron-induzierte 
endotheliale Dysfunktion wurde durch die Entfernung der endothelialen MR Expression 
vollständig verhindert. Ein ähnlicher Schutz vor endothelialer Dysfunktion konnte durch 
Verabreichung des COX-Inhibitors Indometacin erreicht werden. Dies unterstreicht die 
Bedeutung der erhöhten COX-1 und Prostacylin-Synthase Expression in Aorten-Endothelzellen 
bei Fettleibigkeit. Experimente mit Aldosteron-behandelten EC MR KO Mäusen ergaben, dass 
Aldosteron die Expression von Prostacyclin-Synthase auf eine MR-unabhängige Art in Aorten-
Endothelzellen induziert. Wir vermuten, dass der von Aldosteron ausgelöste Anstieg des 
Prostacyclin produzierenden Enzymes maßgeblich zur Entstehung der Fettleibigkeit-
induzierten endothelialen Dysfunktion, beiträgt. Außerdem moduliert Aldosteron die 
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Expression von p22phox und SOD-1 durch Aktivierung des endothelialen MR. Diese durch 
Aldosteron und endothelialem MR ausgelösten Änderungen, die mit oxidativem Stress assoziiert 
werden, spielen eine Schlüsselrolle in der Entwicklung Fettleibigkeit-induzierter endothelialer 
Dysfunktion. 
Wir konnten zeigen, dass der Funktionsverlust des endothelialen MR einen antioxidativen 
Zustand der Aorten-Endothelzellen begünstigt und dadurch zu einer verminderten 
endothelialen Dysfunktion bei Fettleibigkeit führt. Daraus schließen wir, dass der endotheliale 
MR eine massgebliche Rolle bei Adipositas-induzierter endothelialer Dysfunktion spielt. 
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3 Introduction 
3.1 Obesity 
For many centuries, obesity was regarded as a symbol of wealth, healthiness and beauty. But 
over the years it has been recognized that immense corpulence can be associated with various 
life-threatening diseases. 
Nowadays, obesity is defined as a condition where body fat has accumulated to an extent that 
has adverse effects on health, leading to reduced life expectancy and/or increased health 
problems1. A measure that defines obesity is the body mass index (BMI; BMI = kilograms / 
meters2)2. It compares weight and height and defines people as overweight if their BMI is 
between 25 kg/m2 and 30 kg/m2, and obese when it is greater than 30 kg/m2.  
Obesity is most commonly caused by a combination of genetic susceptibility and individual 
behavior as excessive food intake and lack of physical activity (Figure 1). Especially abdominal 
obesity is an important risk factor for development of obesity-associated diseases3-4.    
 
 
Figure 1. The pathology of obesity produces several health-related problems. These health problems 
can be attributed to increased mass of fat or increased release of peptides from enlarged fat cells. GB 
gallbladder, FLD fatty-liver disease. (Figure adapted from5.) 
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The diseases caused by obesity and that arise from increased fat stores can be classified into two 
categories. The first class of disease is consequence of the accumulated fat mass itself like 
respiratory complications during sleep (sleep apnea), osteoarthritis and the stigma of being 
obese as the environmental reactions to the increased body size. The second category arises 
from metabolic changes that are associated with an increased fat mass as diabetes mellitus type 
2, gallbladder disease, hypertension, cardiovascular disease, fatty-liver disease, and some forms 
of cancer associated with overweight (Figure 1)5-6. 
Some of these obesity-favored medical disorders can be summarized, called metabolic 
syndrome7 that is characterized by any of the following factors8: 
 raised fasting plasma glucose and insulin resistance 
 elevated low-density lipoprotein-triglycerides (LDL-Tg) 
 reduced high-density lipoproteins (HDL) 
 raised blood pressure  
 pro-inflammatory state  
 vascular dysfunction 
 pro-thrombotic state 
All of these factors, implicated in obesity, contribute to the genesis of cardiovascular diseases as 
atherosclerosis. 
3.1.1 Obesity-induced insulin resistance 
With the increasing occurrence of the metabolic syndrome in the industrialized world, more 
attention has been drawn to the adipose tissue. Two different types of types of adipose tissue are 
known: the brown adipose tissue (BAT) and the white adipose tissue (WAT). Whereas the 
primary function of the BAT is the control of body temperature, the WAT is traditionally 
regarded as a lipid and energy storage organ that releases and deposits fatty acids.  
Insulin is a pancreatic hormone that regulates carbohydrate and fat metabolism in the body by 
enhancing glucose uptake from the blood in adipocytes, being the major cell-type of the WAT, 
liver and muscle.  Furthermore, insulin inactivates the hormone-sensitive lipase, which is 
responsible for the breakdown of triacylglycerol molecules and mobilizes energy stores in the 
tissue. Increased fasting plasma insulin and an enhanced insulin response to an oral glucose 
challenge is one major characteristic of obesity9.  Interestingly, overweight individuals with most 
of their fat stores in the abdominal depots suffer of greater metabolic consequences than similar 
obese subjects with fat stores predominantly in subcutaneous sites10-11.  
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This is due to the anatomical site of the visceral WAT that drains via the portal venous system. 
Thus, the liver is exposed to an increased repertoire of FFA, glycerol and lactate that is 
enhancing hepatic gluconeogenesis7,12. 
The different fat depots within the body vary in their responsiveness to hormones that 
counteract insulin action and are involved in the regulation of fat breakdown, called lipolysis. 
Because of higher expression of the β1- and-β2-adrenergic receptors12-13 as well as of 
glucocorticoid receptor14, the abdominal WAT shows an increased lipolytic response to the 
neurotransmitter noradrenalin and the glucocorticoid cortisol that enhance the exaggerated 
release of free fatty acids (FFA) from adipocytes into the circulation (Figure 2)15-16. The 
increased FFA in obesity induces hepatic gluconeogenesis, inappropriate glucose release and in 
turn, impaired hepatic glucose tolerance. This contributes to generation of raised circulatory 
insulin concentrations, called hyperinsulinemia. This post-hepatic insulin delivery is increased 
in upper body obesity resulting in increased peripheral insulin concentrations and in turn, due 
to downregulation of the insulin receptors in adipose tissue and muscle, insulin resistance. 
Initially, the β-cells of the pancreas compensate for this process by producing more insulin. In 
time, there is failure of the β-cells and followed by an increase of circulating blood glucose 
concentration, called hyperglycemia and in turn, type 2 diabetes. Hyperinsulinaemia and insulin 
resistance correlate with a dyslipoproteinaemic state and contribute to a obesity-associated 
plasma lipid profile that is characterized by elevated fasting plasma triglyceride concentration, 
reduced high-density lipoprotein (HDL)–cholesterol, elevations of cholesterol and low-density 
lipoprotein (LDL)–cholesterol concentrations6,17. 
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Figure 2. Schematic illustration of the effects of increasing amounts of WAT on whole-body 
sensitivity to the actions of insulin and glucose. (Figure adapted from6.) 
3.1.2 Obesity-induced hypertension 
Obesity, especially visceral obesity, is strongly associated with arterial hypertension18-19.  Since 
expanded lean tissue mass as well as oxidative demands of the metabolically active adipose 
tissue increases in obesity, total oxygen consumption is enhanced. Therefore, the total blood 
volume in obesity is increased in proportion to body weight. The central mechanism to increase 
the blood volume in obesity is enhanced sodium and water retention. Reasons for these changes 
in sodium handling might be a hyperinsulinaemia- and hyperleptinaemia-induced sympathetic 
nervous system activation, as well as activation of the renin-angiotensin-aldosterone-system 
(RAAS)20. Another important reason for the impaired pressure natriuresis in obesity is physical 
compression of the kidney that leads to alterations of intrarenal forces20. The expanded blood 
volume raises the left ventricular preload of the heart and in turn, cardiac output. As blood 
pressure is a function of cardiac output and systemic vascular resistance, the increased blood 
volume in obesity ascends blood pressure6,17. 
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3.1.3 Obesity-induced inflammation 
The WAT is a heterogeneous organ. In addition to adipocytes that are its most abundant cells, 
the WAT contains pre-adipocytes, which are adipocytes that are not loaded with lipids, stromal 
vascular cells, leukocytes and importantly, macrophages.  Besides their function in fat storage, 
WAT is known to be an endocrine organ that releases a wide range of humoral cytokines and 
signaling molecules, called “adipokines”. The most important adipokines, mainly secreted by 
adipocytes, are: leptin, tumor necrosis factor α (TNF-α), adiponectine, interleukin-6 (IL-6), 
monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1), and 
components of the renin-angiotensin-system (RAS)21-22.  
3.1.3.1 Leptin 
The protein hormone leptin is one of the most important adipokines of the WAT. It is mainly 
produced by adipocytes and plays a key role in regulating energy intake by acting on the 
hypothalamus and inhibiting appetite23. Furthermore, leptin influences the development of 
inflammation by inhibiting macrophage-mediated responses24. 
3.1.3.2 TNF-α 
The proinflammatory cytokine TNF-α is secreted by adipocytes25, stromovascular cells26 and 
macrophages27. It is found to be overexpressed in the adipose tissue of rodent models of obesity 
as well as in the adipose tissue of obese humans28-29. TNF-α is involved in the development of 
inflammation and insulin-resistance25.  Adipocyte-derived TNF-α stimulates MCP-1 production 
by preadipocytes 30 and enhances the expression of adhesion molecules as vascular cell adhesion 
molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1) in endothelial cells31. 
These effects of TNF-α mediate the recruitment and adhesion of monocytes into the WAT31.  
3.1.3.3 Adiponectin 
The protein hormone adiponectin is mainly secreted by adipocytes and exhibits antiatherogenic 
and insulin-sensitizing properties32. In response to TNF-α induced inflammation in aortic 
endothelial cells, adiponectin enhances the expression of adhesion molecules as ICAM-1 and 
VCAM-133. Low adiponectin levels are found in coronary artery disease, essential hypertension 
and diabetes mellitus34. 
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3.1.3.4 MCP-1 
MCP-1 is a chemoattractant protein, that can bind to endothelial cells and recruits immune cells 
to the site of inflammation. MCP-1 is mainly produced by macrophages and adipocytes35-37.  Its 
secretion is increased in the adipose tissue in obesity38 and mediates visceral fat-induced 
atherosclerosis in mice39.   
3.1.3.5 IL-6 
The proinflammatory cytokine IL-6 is produced by immune cells and the adipose tissue40. It  
stimulates the synthesis of the acute phase response protein C-reactive protein (CRP) in the liver 
that in turn, activates the complement system41 and has been associated with the development 
of type 2 diabetes mellitus42. 
3.1.3.6 PAI-1 
The serin protease inhibitor PAI-1 is a procoagulative agent since it is the principal inhibitor of 
fibrinolyes. PAI-1 secretion by adipocytes is increased in obesity43 and plays an important role in 
thrombosis44 as well as in tissue remodeling in atherosclerotic lesions in coronary artery 
disease45. 
3.1.3.7 The renin-angiotensin-system 
Adipocytes express all components of the RAS that are required for Angiotensin II (AngII) 
production and signaling: angiotensinogen (Ang), angiotensin-converting enzyme (ACE), renin 
and AngII receptors46-47. Indeed it has been shown that AngII is produced in the adipocytes and 
that the adipocytes themselves are sensitive to AngII48-49.  It has still to be clarified if the AngII 
secreted by adipose tissue plays an important systemic role in the development of vascular 
inflammation and atherogenesis 50. 
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The adipokines produced by the WAT are released in the circulation and may influence other 
organs. Obesity is accompanied by an abnormal production of many adipokines, leading to an 
imbalance of complex interactions, and consequently to metabolic problems (Figure 3)51.  Even a 
moderate weight reduction decreases circulating levels of proinflammatory adipokines as TNF-α 
and IL-652.  
Since there are difference in the production of adipokines between visceral and peripheral fat 
tissue, the site of fat accumulation seems plays an pivotal role in the development of obesity-
induced metabolic changes53. For example, the visceral fat tissue shows higher activity in 
secretion of adipokines as adiponectin, PAI-1 and Ang26. 
 
 
Figure 3. Adipose tissue is a highly active endocrine organ that is involved in the body’s 
metabolism. Adipokines, secreted by the WAT, influence various organs in the body. Since obesity is 
associated with increased production of many adipokines, the homeostasis within the organism is 
disturbed. These pathological changes induce metabolic disorders. (Figure taken from51). 
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Besides dysregulated production of adipokines, the WAT itself is characterized by enhanced 
inflammation with increased infiltration of macrophages and T-cells in obesity30,54. It is 
suggested, that enhanced oxidative stress resulting from an increasingly lipolytic environment in 
obesity, induces physical damage to the endothelium in the WAT (Figure 4). The damaged 
endothelial cells produce MCP-1 as well as TNF-α and recruit macrophages to WAT, in the early 
state of obesity. In turn, the accumulating adipocytes secrete MCP-1, leptin and TNF-α and 
decrease the production of adiponectin; thereby contributing to macrophage accumulation55. 
This results in a viscous cycle of macrophage recruitment, production of inflammatory cytokine 
and impaired adipocyte function55. 
 
Figure 4. Obese adipose tissue is characterized by inflammation and progressive accumulation of 
macrophages. (Figure taken from 54.) 
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3.1.4 Obesity-induced oxidative stress 
3.1.4.1 Reactive oxygen species (ROS) 
Enhanced metabolic stress influences signaling pathways in the cell and in turn alters 
expression of specific genes. One form of such stress is the increased production of ROS. 
Oxidative stress plays a critical role in the development of various diseases and has been shown 
to be increased in obesity56.  It is mainly caused by a dysbalance between the activity of 
endogenous pro-oxidative enzymes such as the NADPH oxidase, mitochondrial respiratory chain 
or xanthine oxidase and anti-oxidative enzymes as the superoxide dismutases (SOD), catalase, 
glutathione peroxidase, and paraoxonase. 
Under physiological conditions, production and degradation of ROS is balanced and therefore, 
the redox state of the cell is well equilibrated.  They can act as second messenger and influence 
signaling cascades, that regulate gene expression and posttranslational modification57-58. 
Increased release of ROS or deficiencies in the antioxidant systems elevate intracellular free 
radical concentration, which may initiate lipid peroxidation and induce pro-inflammatory redox-
sensitive pathways. Two important mediators of transcription of pro-inflammatory genes are 
the redox sensitive transcription factors nuclear factor-kB (NF-kB) and activator protein-1 (AP-
1)59. These transcription factors may induce expression of proinflammatory genes, including 
cytokines, cell adhesion, matrix metalloproteinases and inducible nitric oxide synthase (NOS)60-
61. In turn, increased oxidative stress is central to various cardiovascular diseases such as 
atherosclerosis, congestive heart failure and hypertension62.  
ROS can be divided in 2 different classes: oxygen radical and non-oxygen radicals. The most 
important oxygen radicals are the superoxidanion (O2.-) and the hydroxyradical (OH٠). Since it is 
a precursor of several other radicals, the superoxidanion has central position within the ROS. Its 
most important interaction is the reaction with nitric oxide (NO), leading to a decrease in NO 
bioavailability in the vasculature63 and to the generation of the harmful peroxynitrite (ONOO.)64. 
Non-radical ROS include hydrogenperoxide (H2O2) and hypochloride (HOCl), both of which exert 
harmful effects by favoring free radical production  
3.1.4.2 NADPH oxidases 
One of the most prominent source of ROS in adipocytes and the vascular tissue is the NADPH 
oxidase65-68. This enzyme system catalyzes the transfer of a single electron from cytosolic 
NADPH to molecular oxygen leading to the generation of the superoxide radical. The NADPH 
oxidase complex comprises several subunits. The main component is the heterodimeric 
cytochrom b558 that consists of the membrane-bound subunits p22phox and gp91phox. Its 
prosthetics groups FAD and Heme, that are involved in the electron transition from NADPH to 
the molecular oxygen, are bound by these two subunits69 (Figure 4). In its inactive state, the 
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NADPH oxidase subunits p47phox, p67phox, p40phox and the GTPase Rac are located in the 
cytoplasm. Stimulation by phorbol ester or bacterial toxins induces a proteinkinase C-dependent 
phosphorylation of p47phox and activation of the Rho GTPase Rac. This in turn induces an 
activation and translocation of the cytosolic subunits to the plasma membrane70. The association 
with the subunits p22phox and gp91phox initiates superoxide generation71. The reducing 
substrate NADPH binds on the cytosolic side to the gp91phox subunits and is oxidized. The 
electrons are transferred to FAD, the first and second Heme group and are subsequently 
accepted by molecular oxygen that is thereby reduced to the superoxidanion (Figure 5)72. 
 
 
Figure  5. The non-phagocytotic NADPH oxidase complex. The NOX subunit is bound to p22phox in the 
plasma membrane. Upon activation, the cytosolic subunits translocate to the plasma membrane and allow 
the generation of superoxide. 
 
The catalytic subunit of the NADPH-oxidase gp91phox is a member of a protein family, that 
show high similarity to the neutrophilic NADPH oxidase and are called non-phagocytotic NADPH 
oxidases (NOX)72. NOX2 (also called gp91phox) is mainly expressed in endothelial cells and 
phagocytes, whereas NOX1, NOX4 and NOX5 are localized in endothelial cells, vascular smooth 
muscle cells and other cell types73-74. Adipocytes express exclusively NOX465. NOX3 is primarily 
found in embryonic tissue75. 
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3.1.4.3 Antioxidant systems 
To protect from oxidative damage by ROS, reducing antioxidant systems as superoxide 
dismutase (SOD) or catalase regulate the ROS content in the cell72. SODs are a class of enzymes 
that catalyze the dismutation of superoxide into oxygen and hydrogen peroxide. They are an 
important antioxidant defense in nearly all cells exposed to oxygen. Several common forms of 
SOD exist: cofactored with copper and zinc (SOD-1 and SOD-3) or manganese (SOD-2). Whereas 
SOD-1 and SOD-2 are located intracellular, the SOD-3 is located extracellular between the 
endothelium and the vascular smooth muscle cells (VSMCs). Catalase is another intracellular 
antioxidant system that catalyzes the decomposition of hydrogen peroxide to water and oxygen. 
3.1.4.4 ROS action in WAT 
Indeed, a direct correlation between obesity and oxidative stress, assessed by measuring F2-
isoprostanes, has been demonstrated in humans56. Isoprostanes are prostaglandin-like products 
that are formed in vivo via a non-enzymatic mechanism and involve the free radical-mediated 
peroxidation of arachidonic acid. F2-isoprostanes measured in the plasma and in the urine are 
biomarkers for lipid oxidation and therefore for oxidative stress76. Besides obesity, F2-
isoprostanes are increased in diabetes77, hypercholesterolemia78 and end-stage renal disease79.  
Furukawa and colleagues65 demonstrated that ROS production is increased in the entire adipose 
tissue of mice and cultured adipocytes. This increased oxidative stress is accompanied by 
enhanced expression of the NADPH oxidase as well as attenuated expression of SOD-3 and 
catalase in the WAT65. This is in line with another publication showing attenuated SOD-3 
expression in obesity, thereby contributing to enhanced oxidative stress80-81. The adipose tissue 
derived ROS in obesity dysregulates the expression of adipokines as adiponectin, PAI-1, IL-6 and 
MCP-1. Inhibition of the NADPH oxidase resulted in attenuated ROS production, normalized 
adipokines production and ameliorated diabetes and hyperlipidemia65.  
Taken together, the increased oxidative stress in obesity might enhance proinflammatory 
changes in remote tissues in two ways: directly, by activating redox-sensitive nuclear 
transcription factors as AP-1 and NF-κB and indirectly, by dysregulating adipokines expression 
in the WAT that in turn may affect target tissues. The proinflammatory changes in target tissues 
might contribute to development of insulin resistance, diabetes and atherosclerosis (Figure 6). 
Thus, the proinflammatory and pro-oxidant effects in obesity may link obesity and 
cardiovascular disease. 
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Figure 6. Increased ROS production in accumulated fat contributes to metabolic syndrome. (Figure 
taken from65). 
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3.2 Blood vessel wall 
3.2.1 Structure of the blood vessel  
The blood vessels are an important part of the cardiovascular system as they distribute the 
blood, oxygen and nutrients to the organs, and remove the waste products from tissues 
throughout the body. All blood vessels, except capillaries, have the same basic anatomical 
structure (Figure 7).  
The tunica intima is the inner layer of a vessel, consisting of one coat of endothelial cells and is in 
direct contact to the flowing blood in the vessel. The endothelium separates the blood from the 
deeper layers (elastic interna and the underlying vascular smooth muscle).  
The tunica media consists, depending on the type of vessel, of a more or less pronounced layer of 
VSMCs that is lined on both sides by an elastic lamella of connective tissue. The tunica media is 
responsible for the regulation of the vascular tonus and is a target of hormonal and neuronal 
signals82. 
The outer layer, the tunica externa (adventitia) consists mainly of fibroblasts and connective 
tissue that anchors the vessel in the surrounding tissue. In addition, nerves and nutrimental 
blood vessels can be located in tunica externa 83. 
 
 
Figure 7.  Structure of a muscular artery. The three structural components of the blood vessel, the 
intima, media and adventitia are indicated. Mechanical forces as pressure (p) and shear stress ( ) act 
luminal on the vessel wall. (Figure adapted from84.) 
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3.2.2 The endothelium 
The endothelium is the largest organ in the body. It forms the border between the circulating 
blood in the vessel lumen and the rest of the vessel wall. The endothelium senses mechanical 
stimuli such as pressure, shear stress (Figure 7) and hormonal stimuli, such as vasoactive 
substances. The various functions of the endothelium comprise the regulation of the vessel tone, 
control of endothelial permeability and inhibition of thrombocyte aggregation, thrombocyte and 
leukocyte adhesion on the vessel surface and smooth muscle cell growth85-86. These effects are 
controlled by various growth factors and vasoactive mediators that influence the physical and 
biochemical properties of the vessel.  
The vascular tone of the vessel is determined by a well-orchestrated release of vasodilators and 
vasoconstrictors. The most important endothelium-derived relaxing factors (EDRF) are NO and 
prostacyclin (PGI2). Endothelium-derived contracting factors (EDCF) comprise endothelin-1, 
ROS, angiotensin-II, thromboxane A2, prostaglandin F2α and under pathophysiological conditions,  
prostacyclin87-89.  
Since it has been discovered, that the neurotransmitter acetylcholine requires intact endothelial 
cells to induce arterial vasodilatation, the importance of the endothelium for vascular 
homeostasis has been increasingly recognized90 (Figure 8). Under physiological conditions the 
neurotransmitter acetylcholine binds to specific G protein coupled receptors on endothelial cells 
and the downstream signaling pathway leads to phosphorylation and activation of the 
endothelial nitric oxide synthase (eNOS)91. The eNOS uses L-arginine as substrate to generate L-
citrulline and NO in a NADPH-and O2-dependent manner. NO produced in the endothelial cells 
diffuses into the underlying VSMCs and stimulates the NO-sensitive guanylylcyclase (GC); the 
most crucial receptor for NO92-93. The GC induces cyclic guanosin monophosphate (cGMP) 
production by activating soluble GC. In turn, cGMP mediates than most of its intracellular actions 
by activating cGMP-dependent protein kinases (PKG), that influences the vascular tone of the 
VSMC92. Besides from eNOS two other isoforms have been identified so far : the inducible NO 
synthase (iNOS) and the neuronal NO synthase (nNOS)91,94. Nevertheless, eNOS seems to play the 
most prominent role in inducing endothelium-dependent vasodilation in the healthy and 
diseased vessel95-96. NO is the major endothelium-derived relaxing factor in the vascular system. 
In addition, NO exerts vascular protective effects such as prevention of monocyte adhesion to 
the endothelial layer, reduction of smooth muscle cell proliferation, and inhibition of platelet 
activation and aggregation97. 
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Another important EDRF is PGI2, the principal metabolite of arachidonic acid in endothelial 
cells98-99.  Acetylcholine induces the generation of PGI2, from arachidonic acid in several 
enzymatic steps, including the cyclooxygenase (COX) and prostaglandine synthase. PGI2 is the 
preferential ligand for the prostacyclin receptor (IP) on smooth muscle cells that activates AC 
and thus elevates intracellular cAMP. This induces vasodilation100. 
 
 
 
Figure 8. Mechanism of endothelium-dependent relaxation by acetylcholine. M muscarinic receptor, 
eNOS endothelial NO synthase, NO nitric oxide, sGC soluble guanylatecyclase, cGMP cyclic guanosin 
monophosphate, PLA2 phospholipase 2, COX cyclooxygenase, PGI2 prostacycline, IP prostacyclin receptor. 
(Figure adapted from89,101.) 
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3.2.3 Endothelial dysfunction 
An intact endothelium is required for healthy physiological vascular function. The protective 
function of the endothelium can be impaired by various factors as infections, systemic or local 
inflammation, hypertension, pharmaceuticals and metabolic disorders. Loss of proper 
endothelial function may lead to chronic endothelial dysfunction that is an important early step 
in atherogenesis102. It appears years before any obvious clinical, pathological changes of the 
vessel wall are observed. 
Endothelial dysfunction has been associated with diseases contributing to the development of 
cardiovascular diseases as hypertension103, obesity  and metabolic syndrome104-105, type 1 and 
type 2 diabetes106-107 as well as with cardiovascular disease itself like, coronary artery disease108, 
congestive heart failure109, chronic renal failure110. Endothelial dysfunction is characterized by a 
shift of actions of the endothelium towards reduced vasodilation or even vasoconstriction, a 
proinflammatory state, and prothrombotic properties. Impaired endothelium-dependent 
vasodilatation may arise from several mechanisms including: decreased production of one of the 
EDRFs, enhanced inactivation or impaired diffusion of these EDRFs to the underlying smooth 
muscle cells and enhanced generation of EDCFs. 
3.2.3.1 Decreased production of EDRF NO 
NO is one of the most important vasodilatory substances released by the endothelium. Reduced 
NO levels are often associated with endothelial dysfunction97. These reduced amounts of NO 
might be due to a decreased eNOS activity or a decreased bioviability of NO. Increased oxidative 
stress, which is often observed in patients with hypertension, hypercholesterolemia or diabetes, 
impairs NO production and chemically quenches NO by formation of toxic peroxynitrite97,111. In 
addition, superoxide enhances the degradation of 4-tetrahdrobiopterin (BH4), a cofactor of 
eNOS, leading to ‘uncoupled’ eNOS. This means that the oxygen reduction is uncoupled from the 
NO synthesis, thereby yielding a dysfunctional superoxide generating enzyme that produces ROS 
and therefore enhance vascular oxidative stress112-113.   
3.2.3.2 Enhanced generation of EDCF 
ROS 
The NADPH oxidase is the most important source of ROS in endothelial cells and VSMCs 
in  quiescence and under stimulation67-68. As already mentioned above, the NADPH oxidase-
derived ROS reduces NO bioavailability. In addition to that, ROS induce vasoconstriction directly 
and enhance redox-sensitive transcription factors as NFκB that can initiate vascular 
inflammation114-115. ROS also induce lipid peroxidation, endothelial cell apoptosis, matrix 
metalloproteinase (MMP) expression and proliferation of vascular smooth muscle cells. All of 
these effects promote endothelial inflammation and dysfunction116. Indeed, in animal models of 
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diabetes, increased oxidative stress enhances the development of endothelial dysfunction117-118.  
In hypertension and chronic renal failure, it has been shown that treatment with antioxidants 
modulate enzyme systems that generate free radicals, namely NADPH oxidase and SOD119-120 in a 
beneficial way and attenuate endothelial dysfunction by increasing eNOS activity121.  Beneficial 
effects of antioxidant treatment has been also observed in endothelial dysfunction associated 
with obesity122.  
Angiotensin II 
AngII contributes to the development of hypertension and endothelial dysfunction by inducing 
vasoconstriction and by enhancing NADPH oxidase generated ROS in aortic endothelial cells123-
127.  
Prostanoids 
Endothelial dysfunction can be due to the enhanced release of endothelium-derived contracting 
factors that counteract via prostanoids receptors (TP) the vasodilatory action of NO. These 
endothelium-derived contractions involve the endothelial COX-1 and COX-2 activation and 
release of various prostanoids that activate the TP on the underlying vascular smooth muscle 
cells. This in turn, results in vasoconstriction of the vessel (Figure 9)89,128. 
Prostanoids are a subclass of eicosanoids consisting of prostaglandins, thromboxanes and 
prostacyclins. They are enzymatically derived from fatty acids and exert physiological effects, 
such as relaxation and contraction of smooth muscle tissue89. Arachidonic acid, the most 
common precursor of prostaglandins, is generally produced from phospholipids by 
phospholipase A2 (PLA2) and can be metabolized either via the lipoxygenase pathway to form 
leukotriens or via the cyclooxygenase pathway to form prostaglandins. Prostaglandins are 
produced following sequential oxidation by COX and terminal prostaglandin synthases129.  
The cyclic endoperoxide Prostaglandin H2 (PGH2), produced by COX, can be metabolized into 
prostaglandin D2 (PGD2) by the PDG synthase, into prostaglandin E2 (PGE2) by the PGE synthase, 
into prostacyclin (PGI2) by the prostacyclin synthase and into thromboxane (TXA2) by the 
thomboxane synthase, respectively. 
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Figure 9. Mechanism of endothelium-dependent contractions by prostanoids. The red color 
indicates pathophysiological changes that can contribute to endothelium-dependent contractions. M 
muscarinic receptor, PLA2 phospholipase 2, COX-1 cyclooxygenase-1, COX-2 cyclooxygenase-2, PGH2 
prostaglandin H2, PGD2 prostaglandin D2, PGE2 prostaglandin E2, TXA2 thromboxane, PGI2 prostacycline, TP 
prostanoid receptor, IP prostacyclin receptor, SR sarcoplasmatisches reticulum. (Figure adapted 
from89,101.) 
 
COX-1 is expressed in most tissues constitutively, while COX-2 is induced mainly at sites of 
inflammation130. Enhanced endothelial expression of COX-2 enhances endothelial contraction in 
aged and hypertensive rodents131-132. Inhibition of COX by indometacine abolishes endothelial 
dysfunction in diabetic rats whereas COX-1 derived products seem to play the major role in this 
case133. 
Prostaglandins bind seven-transmembrane, G-protein-coupled receptors, most importantly to 
mention because they are expressed on endothelial cells are the TP and the IP. TXA2, PGH2 and 
other prostaglandins can activate the TP134 and promote vasoconstriction by increasing 
intracellular calcium. Furthermore, they enhance expression of adhesion molecules and platelet 
aggregation135. 
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As already described above, PGI2 acts as a vasodilator under physiological conditions by binding 
to the IP receptor98-99. Paradoxically, PGI2 has been show to be a major constricting factor in 
hypertension. Because of specific dysfunction of the IP in the VSMC, PGI2 binds to the TP and 
induces TP-dependent contractions136-137. 
3.2.3.3 Effects of adipokines on endothelial dysfunction 
As endothelial dysfunction is one of the early stages of atherosclerosis, it is reasonable to 
appreciate that adipokines, secreted by the WAT in obesity, might have a direct impact on 
endothelial cells and contribute to the development of endothelial dysfunction. 
It has been shown that increased leptin levels under caloric restriction improve acetylcholine-
induced NO-dependent vasorelaxation in the rat aorta138. In addition, endothelium-dependent 
relaxation is deteriorated in subjects with low plasma adiponectin levels 139. In the liver, the 
cytokine IL-6 stimulates the synthesis of acute-phase response proteins such as CRP, which 
induce endothelial dysfunction140. Similarly, TNF-α induces enhanced endothelial permeability 
by activating NADPH oxidase141 and inhibits transcriptional and post-transcriptional eNOS gene 
expression142. Both of these effects are known to enhance endothelial dysfunction. Besides from 
the strongly altered secretion of adipokines, obesity is associated with increased concentrations 
of FFA in the plasma. Increased plasma levels of the FFA oleic acid inhibits eNOS activity in aortic 
endothelial cells in vitro143 and impairs endothelial function in healthy subjects in vivo144. Thus, 
adipokines and FFA contribute directly to the development of endothelial dysfunction in obesity. 
3.2.4 Pathophysiological effects of endothelial dysfunction 
Apart from an impaired vasodilation, endothelial dysfunction is characterized by a pronounced 
proinflammatory state. Low NO bioavailability and enhanced oxidative stress in endothelial cells 
results in the activation of the redox-sensitive NF-κB signaling pathway. Activated NF-κB 
migrates into the nucleus and induces the expression of numerous genes, including many pro-
inflammatory genes such as E-Selectin, ICAM-1, and VCAM-161,145. These endothelial cells are 
considered ‘activated’. In contrast, under physiological conditions aortic endothelial cells do not 
express these adhesion molecules, except for low constitutive levels of ICAM-1146.  
Presentation of these molecules play a role in the initiation of inflammatory process since they 
attract and activate blood monocytes, which then transmigrate into the arterial intima. NO 
inhibits leukocyte adhesion147. This transmigration of monocytes is stimulated by chemokines, 
such as MCP-1, MCP-4, regulated on activation normal T cell expressed and secreted (RANTES), 
and IL-8, which bind to G protein coupled-receptors and are expressed by various vascular 
cells148. 
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Adhesion of mononuclear phagocytes to the activated endothelial layer starts early in 
atherogenesis149, suggesting that endothelial activation is an early inflammatory step of the 
disease. Subendothelial macrophages transform into lipid-laden foam cells, they scavenge 
oxidized LDL through receptors such as LOX-1150. As the atherosclerotic plaque grows, growth 
factors that are secreted by macrophages in the plaque, stimulate vascular smooth muscle cell 
proliferation and interstitial collagen synthesis151. Decreased NO and increased oxidative stress 
active MMP-2 and MMP-9 that may weaken the fibrous cap151-152 and eventually lead to the 
rupture of the thin fibrous cap, thrombus formation with complete coronary occlusion, and 
myocardial infarction. All these proinflammatory events, participating in atherogenesis, 
underline the concept that atherosclerosis is a chronic inflammatory disease152.  
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3.3 Aldosterone and the renin-angiotensin system 
The RAAS is a hormone system that regulates blood pressure and volume homeostasis. Low 
blood pressure induces the juxtaglomerular cells in the kidneys to secrete renin. Renin 
stimulates the production of α2-globulin Ang in the liver and cleaves Ang into the decapeptide 
AngI. In turn, AngI is cleaved by the endothelial enzyme ACE into the octapeptide Ang II (Figure 
10). By binding to its receptor, AT1 receptor (type I ANG II receptor), Ang II can act directly as a 
potent vasoconstrictor. In addition, Ang II induces renal sodium reabsorption, stimulates thirst 
and AVP secretion in the central nervous system (CNS). Furthermore, it induces a signaling 
pathway in glomerulosa cells of the adrenal gland that results in increased aldosterone synthesis 
and release. Ang II also binds to AT2 receptors (type II ANG II receptor) inducing a counter 
regulatory vasodilation. The final endocrine hormone of the RAAS is the mineralocorticoid 
aldosterone that is the prime regulator of salt balance and extracellular volume in the body17,153. 
 
Figure  10. The renin-angiotensin-aldosterone axis. JGA juxtaglomerular apperatus.(Figure taken from 
the Textbook Boron & Boulpaep17) 
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3.3.1 Aldosterone  
Aldosterone regulates the blood volume by increasing Na+ absorption in the distal kidney 
tubules and collecting ducts in exchange for K+. This causes enhanced retention of water, which 
elevates the extracellular fluid volume and in turn, raises arterial pressure. Moreover, 
aldosterone enhances blood pressure by inducing vasoconstriction in the vasculature and 
influences the central nervous system directly154. Since aldosterone plays a key role in the 
maintance of blood pressure, its release is tightly regulated by the RAS, extracellular K+ and 
ACTH (adrenocorticotropic hormone). Furthermore, plasma acidosis and stimulation of stretch 
receptors, located in the atria of the heart, can enhance aldosterone secretion155-156. Over a 24h 
period, aldosterone displays an episodic secretory pattern, whereas mean plasma levels, pulse 
frequency and amplitude increase during the night and the early morning hours, in humans157. 
Aldosterone belongs to the class of steroid hormones and is synthesized from cholesterol in a 
series of five steps (Figure 11). The last of these steps is the conversion of corticosterone to 
aldosterone, catalyzed by the aldosterone synthase (cytochrome P-450 CYP11B2).  
 
Figure 11. Aldosterone synthesis form cholesterol. (Figure adapted from17.) 
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The aldosterone synthase, primarily expressed in the cortical adrenal gland of the kidney, 
controls the aldosterone secretion in the circulation. Even more, aldosterone can be produced in 
extrarenal tissues such as the heart158 and the vascular system159. At the vascular level, 
aldosterone production has been demonstrated clearly in smooth muscle cells160 whereas 
aldosterone production in vascular endothelial cells is still debated66,161. 
3.3.2 Mineralocorticoid receptor 
Since aldosterone is a steroid hormone, it can freely diffuse through the plasma lipid membrane 
of the cells. In the cytoplasm, the hormone can bind to two different receptors; its low-affinity 
receptor, the glucocorticoid receptor (GR) and more importantly, its high-affinity receptor the 
mineralocorticoid receptor (MR). The MR, is also known as aldosterone receptor, or nuclear 
receptor subfamily 3, group C, member 2, (NR3C2) belongs to the steroid receptor subfamily, 
together with the glucocorticoid, progesterone and androgen receptors. 
Steroid receptors display a modular structure comprised of three major functional domains 
(Figure 12). A N-terminal domain (NTD), followed by a central DNA-binding domain (DBD), and 
a hinge region that links them to the C-terminal ligand-binding domain (LBD). The human MR 
gene consists of 10 exons, including 2 untranslated first exons (1α and 1β). The translation start 
codon AUG starts at exon 2, whereas the stop codon UGA is located in exon 9. Exon 2 encodes 
most of the NTD, exons 3 and 4 encode each of the two zinc fingers of the DBD. Exons 5 to exon 9 
encode for the LBD and mediate numerous functions, including ligand binding and interaction 
with heat-shock proteins162. 
 
 
Figure 12. Schematic representation of human MR structure. NTD N-terminal domain, DBD DNA-
binding domain, LDB ligand-binding domain. (Figure adapted from162.) 
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The MR itself can be activated upon binding of aldosterone and cortisol163. Since cortisol has the 
same affinity to the MR as aldosterone and circulates at much higher concentrations in the 
plasma, only removal of the cortisol from aldosterone-targeted tissues enables aldosterone 
action. Indeed, various tissues express an enzyme called 11β-hydroxysteroid dehydrogenase-2 
(11β-HSD2) that converts cortisol into its 11-keto analogs cortisone, which has lower affinity to 
the MR (Figure 13)164-165. As a result, locally within a target cell, the actual cortisol/aldosterone 
ratio is much smaller than the cortisol concentration seen in the plasma. Classical 
mineralocorticoid targets in the kidney, as the distal convoluted tubule and the initial cortical 
collecting duct, express high levels of 11β-HSD2166. Additionally, 11β-HSD2 protein has been 
detected in cardiac myocytes167, vascular smooth muscle cells 168-169 and aortic endothelial 
cells170-172, emphasizing their role as aldosterone target cells. 
Tissues that do not express 11β-HSD2 are resistant to aldosterone-induced MR activation. Even 
more, cells can express the 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) that mediates 
reduction of cortisone to the active hormone cortisol and serve as tissue-specific amplifier of 
glucocorticoid action173. 11β-HSD1 is found in metabolic tissues as the liver, adipose tissue, and 
the CNS. In these tissues, cortisol activates both the MR and GR. 
 
Figure 13. Hydroxsteroid dehydrogenase action. The tissue-specific enzyme 11β–HSD2 converts 
cortisol to MR-inactive cortisone in a NADPH-dependent manner.  Vice versa, 11β–HSD1 converts the 
inactive cortisone into the active cortisol. 
 
The major role of aldosterone is to regulate ion transport. Accordingly, the MR is expressed in 
epithelial tissues in which Na+ transport is regulated such as the distal nephron of the kidney, 
the distal colon, the sweat glands as well as the salivary glands. Beyond its expression in these 
epithelial tissues, the MR is detected in the brain and pituitary174-175 as well as in the cardiac and 
vascular system170-171,176-177. 
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In an unliganded state, the MR is located in the cytoplasm and is complexed with the chaperones 
heat shock proteins 70, heat shock protein 90 and immunophilins162,178. Upon binding with 
aldosterone, the receptor-ligand complex dissociates from chaperons and translocates into the 
nucleus. In the nucleus, the MR directly binds to the DNA at its cognate binding site called 
steroid response element (SRE). The SRE is located in the regulatory region of target gene 
promoters and enhances gene expression. Furthermore, the activated MR can interfere with or 
induce transcription by protein-protein interactions with other factors that influence gene 
transcription162. 
In classical polarized epithelial tissues, aldosterone-activated MR induces the Na+ absorption 
from the lumen by inducing the expression of amiloride-sensitive epithelial sodium channel 
(ENaC) at the apical membrane179-180 and enhancing the activity of the Na+/K+-ATPase on the 
basolateral membrane. K+ diffuses passively to the lumen through K+ channels at the apical 
membrane. Along these lines, the MR alters the expression of serum-and glucocorticoid-induced 
kinase 1 (SGK1), neuronal precursor cell expressed developmentally downregulated 4 (nedd4), 
nedd4 isoform 2 (nedd4-2), K-Ras2A, and caspacin. All these mediators influence the expression 
of the ENaC and Na+/K+-ATPase in the cortical collecting ducts and distal tubules of the kidney, 
thereby modulating Na+ reabsorption and K+ secretion166,181-182. 
Additionally, MR activation by aldosterone induces rapid, non-genomic effects; they are 
insensitive to transcription inhibitors and comprise several second messenger systems: Various 
studies demonstrated that MR signaling enhances the extracellular-regulated kinase/mitogen-
activated protein (ERK/MAP) kinase pathways, the IP3 (inositol 1,4,5-trisphosphate)/Ca2+ 
pathway as well as phosphorylation of c-SRC, JNK and NFκB183-186. Another non-genomic 
response of aldosterone involves an unidentified membrane receptor besides the MR187. It has 
been shown in MR knockout mice that aldosterone treatment enhances Ca2+ and cAMP in 
fibroblasts and skin cells within minutes, independently of the MR183,188. In addition to the 
above-described actions, the activated MR is able to cross-activate other receptors, such as the 
epidermal growth factor and the AT1166. 
3.3.3 Role of aldosterone in hypertension 
As described in the previous sections, aldosterone plays an important role in regulating blood 
pressure. Various clinical studies described that hyperaldosteronism is a common cause of 
resistant hypertension189. Especially the pathophysiological overproduction of aldosterone by an 
adrenocortical adenoma (Conn`s syndrome) induces sustained hypertension190. Furthermore, it 
has been demonstrated in an animal model of spontaneously hypertensive rats, that cardiac and 
vascular aldosterone production contribute the development of hypertension 191-192. 
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For many years, inhibition of ACE and angiotensin receptor blockers (ARB) were used to lower 
aldosterone levels and treat its deleterious effects193. Surprisingly, aldosterone levels further 
increased, even if ACE inhibitors and ARBs were administered, the so-called “aldosterone-
escape” phenomenom193-195. The reason for aldosterone-escape is still incompletely understood, 
but might be due to incomplete ACE inhibition or multiple pathways of aldosterone secretion194. 
Therefore, the direct blockade of the MR seems to be the best way to prevent the harmful effects 
of aldosterone excess. 
Spironolactone, a well-known MR antagonist, was discovered in 1960, and has been proved to be 
very effective for treatment of resistant hypertension196. Due to its anti-androgenic properties, 
spironolactone shows unwanted side effects like gynaecomastia and impotence in males, and 
menstrual disturbances in females197. Therefore, a new more selective MR antagonist though 
with lower affinity, eplerenone, was developed and approved in 2002. MR blockade by 
eplerenone is beneficial in treating essential hypertension as a diuretic that improves blood 
pressure, left ventricular hypertrophy and proteinuria198. Eplerenone is marketed by Pfizer as 
Inspra. 
3.3.4 Role of aldosterone in obesity 
Obesity is associated with hypertension. One of the central reasons is chronically enhanced 
sodium and water retention due to enhanced RAAS activation 20. Indeed, diverse clinical studies 
showed a correlation between visceral obesity and increased plasma aldosterone levels199-202. 
Along this line, weight loss of obese humans is associated with attenuation in plasma 
aldosterone levels and arterial blood pressure202-203.The importance of aldosterone in obesity-
induced hypertension has been shown in a study with diet-induced obese dogs. MR antagonism 
clearly abolished obesity-induced sodium retention and hypertension204. Besides aldosterone, 
plasma Ang205 and plasma ACE activity are increased in obesity203. In contrast, renin activity is 
not enhanced in obesity suggesting renin-independent aldosterone secretion in obese 
subjects199,202. 
Obesity is characterized by increased plasma fatty acid levels and oxidative stress. Therefore, the 
potential stimulatory function of oxidized fatty acids on aldosterone secretion was investigated. 
Indeed, an oxidized derivate of linoleic acid, 12,13-epoxy-9-keto-10(trans)-octadecenoicacid 
(EKODE), stimulates aldosteronogenesis in rat adrenal glomerulosa cells206. Plasma EKODE 
concentration correlates with aldosterone levels and BMI in humans207. In addition to oxidized 
fatty acid-induced aldosteronogenesis, it has been shown, that human adipocytes secrete potent 
aldosterone-releasing factors (ARFs) that induce aldosterone synthase expression and 
aldosterone production in human adrenal adrenocortical cells208-209. In addition to MR activation 
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by the increased aldosterone levels in obesity, the MR might be activated by increased ROS 
levels in obesity. Indeed, it has been demonstrated in a rat model of mild hypertension that ROS-
activated MR enhances cardiac NADPH oxidase activity and dysfunction, 210. 
Taken together, oxidized fatty acids as EKODE and so far unidentified ARFs, produced by the 
WAT induce adrenal aldosterone synthesis and in turn, increase aldosterone levels in obesity. 
Besides an aldosterone-mediated MR activation in obesity, the adipose tissue derived ROS in 
obesity might as well induce MR activation in aldosterone-sensitive tissues and contribute to the 
pathophysiological changes that are associated with obesity (Figure 14)211. 
 
 
Figure 14. The mechanism for MR-activation in obesity. (Figure adapted from211.) 
 
The enzyme 11β-HSD1 plays a crucial role in determining the intracellular glucocorticoid 
levels173. Interestingly, activity and expression of 11β-HSD1 is enhanced in obese adipose 
tissue212-213 and is associated with the development of obesity and metabolic syndrome214-215. 
Since adipocytes express a functional MR that can bind glucocorticoids with equal affinity as 
aldosterone, the increased glucocorticoid levels may also account for MR-mediated effects in 
adipocytes216-218. 
MR blockade in obesity decreases oxidative stress in WAT that might have positive effects on 
adipocytes dysfunction and, in turn insulin resistance216. Furthermore, MR antagonism 
attenuates obesity-induced expression of 11β-HSD1 as well as  pro-inflammatory factors like 
TNF-α, MCP-1, PAI-1 and macrophage infiltration in the WAT216,219. In addition, MR blockade 
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reverses obesity-induced gene repression of adiponectin and PPAR-y (peroxisome proliferator-
activated receptor-y) in adipose tissue216,219. Both adiponectin and PPAR-y are known to 
increase insulin sensitivity220-221. Thus, obesity-induced MR activation in the WAT enhances ROS 
generation and inflammation that might contribute to the development of obesity-related insulin 
resistance217. 
Indeed, various publications support an important role of aldosterone in the development on 
insulin resistance. A low insulin sensitivity in healthy subject can be correlated with increased 
aldosterone plasma levels222. Furthermore, hyperaldosteronism-induced insulin resistance can 
be successfully attenuated by MR antagonism223. Experiments in rats have shown that 
aldosterone administration diminishes insulin responsive glucose transporter (GLUT) 4 
expression in skeletal muscle, as well as insulin-responsive GLUT 2 in the liver. These 
observations may account for skeletal muscle and hepatic insulin resistance in aldosterone-
infused mice224. Studies in genetically obese mice revealed that MR antagonism improved 
glucose tolerance and decreased fasting levels of trigylcerides216,219. Furthermore, aldosterone 
degrades the insulin receptor substrate (IRS) 1 and IRS2 in cultured adipocytes. This 
degradation is induced by an glucocorticoid-receptor-mediated production of ROS and results in 
impaired insulin-induced glucose uptake225. 
Taken together, high aldosterone levels in obesity may not only contribute to hypertension, but 
also to insulin resistance and other components of the metabolic syndrome such as 
hyperlidipdemia, inflammation and oxidative stress which contribute to cardiovascular disease. 
3.3.5 Role of aldosterone in cardiovascular disease 
MR blockade by spironolactone or eplerenone are efficient treatments of hypertension196,198 and 
confers  cardiovascular protection independent of its beneficial effects on diuresis and blood 
pressure. MR antagonists have been reported to reduce morbidity and mortality in patients with 
congestive heart failure 226-227 and exert beneficial effects on patients with systolic heart failure 
and mild symptomes228. Since these effects are out of proportion given the modest diuretic effect 
of MR antagonists, MR action seems to have direct effects on cardiovascular tissue. This is 
supported by the observation that patients suffering from primary aldosteronism experience 
more cardiovascular events than patients suffering exclusively from essential hypertension229.  
Therefore, most harmful effects of aldosterone seem to be blood pressure-independent and are 
most likely carried out by direct action on the vasculature. Indeed, the MR is expressed in both 
aortic endothelial cells and in vascular smooth muscle cells and its expression is enhanced in 
certain pathological conditions as hypertension191. 
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3.3.6 Role of aldosterone in endothelial activation and 
atherogenesis 
Under normal conditions, endothelial cells resist prolonged contact with blood leukocytes. 
However, when activated by various stimuli such as oxidative stress or proinflammatory 
cytokines, endothelial cells express adhesion molecules, thus facilitating attachment and 
migration of leukocytes in the vessel wall and promoting an inflammatory response230-231. 
Indeed, various studies could show the contribution of aldosterone to proinflammatory cardiac 
and vascular responses. In the heart, administration of aldosterone is associated with increased 
expression of proinflammatory markers such as ICAM-1, MCP-1, TNF-α, osteopontin and COX-2. 
Moreover, aldosterone induces accumulation of macrophages and lymphocytes, as well as 
proliferation of fibroblasts in the coronary arteries of rats232-233. Further, MR antagonists 
diminish MMP-2 expression and oxidative stress in a mouse model of left ventricular 
hypertrophy234.  
In the vasculature, MR antagonism decreases atherosclerotic lesions in mice by diminishing 
aortic ROS production, and MCP-1 expression without influencing blood pressure235. 
Furthermore, chronic MR antagonism attenuates aortic COX-2, IL-1β, IL-6 and TNF-α expression 
in normo- and hypertensive rats236. In coronary artery smooth muscle cells, aldosterone 
enhances proinflammatory and profibrotic changes by inducing the expression of lymphocyte 
chemoattractant factor IL-16 and cytotoxic T-lymphocyte–associated protein 4169. In vascular 
endothelial cells the MR promotes ICAM-1 expression and leukocyte adhesion 170. Furthermore, 
aldosterone increases osteopontin and ACE expression in aortic endothelial cells, which may be 
involved in the development of endothelial dysfunction and vascular injury162. Taken together, 
aldosterone induces cardiac and vascular inflammation via the vascular MR. 
3.3.7 Role of aldosterone in endothelial dysfunction 
Endothelial dysfunction is the initial step in the development of atherosclerosis and is 
characterized by a shift of the actions of the endothelium toward impaired vasodilation, a 
proinflammatory and prothrombotic state237. Several studies report that aldosterone 
contributes to endothelial dysfunction: Studies with young healthy subjects have shown that 
acute administration of aldosterone induces endothelial dysfunction, without affecting blood 
pressure238. A study with normotensive and hypertensive rats revealed that aldosterone 
administration induces endothelial dysfunction independent of blood pressure239. Furthermore, 
two different models of atherosclerosis in nonhuman primates and rabbits showed that 
blockade of the MR using Eplerenone ameliorates endothelial function without changing blood 
pressure or total cholesterol240-241. Endothelial cells respond to aldosterone with an increase in 
cell volume by intracellular accumulation of organic matter. This induces swelling of the 
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endothelial cells and stiffness of the vasculature242-243. These observations suggest that 
aldosterone influences endothelial function via non-hemodynamic mechanisms: One important 
pathway can be the decreased bioavailability of NO, leading to impaired endothelial-relaxation 
of the vessel. The decrease in NO can be attributed to decreased amount of NO production and 
increased NO inactivation by ROS244. 
Experiments in rats demonstrate that MR antagonism using eplerenone prevents a decrease in 
eNOS expression in hypertension245 and heart failure246. Aldosterone diminishes eNOS through 
at least two different mechanisms. First, aldosterone reduces NO production by 
dephosphorylation of the N-terminal 1177 serine residue of eNOS, resulting in inactivation of 
the enzyme247. Second, aldosterone reduces expression of the eNOS cofactor BH4 leading to 
uncoupling of eNOS function247. This means that in absence of BH4, eNOS produces ROS instead 
of NO248. Moreover, aldosterone has been shown to inhibit iNOS in vascular smooth muscle cells 
via enhance IL-1β signalling249. 
On the other hand, aldosterone can increase oxidative stress by both increasing ROS production 
and reducing ROS scavenging capacity in the cells. It has been shown, that aldosterone impairs 
endothelial function by decreasing glucose-6-phosphate dehydrogenase (G6P-DH) expression 
via cyclic AMP-response element modulator (CREM) induction and subsequent cAMP inhibiton. 
Overall, the decreased G6P-DH expression and activity impairs its reducing properties 
concerning oxidation of NADP+ to NADPH and results therefore in increased oxidative stress171. 
Moreover, in a rat model of heart failure, spironolactone added to an ACE inhibitor improves 
endothelium-dependent aortic relaxation, most likely by suppression of superoxide 
formation250. 
Aldosterone administration has been shown to increase superoxide production in cultured 
ventricular myocytes251, rat VSMCs252 and rat aortic endothelial cells218,253. Furthermore, 
aldosterone-induced ROS production has been observed in different pathological situations 
since aldosterone enhances and eplerenone attenuates expression of NADPH oxidase subunits 
and oxidative stress in hypertensive rats254, rat hindlimb ischemia255 , a mouse model of left 
ventricular hypertrophy 234 as well as in different animal models of atherosclerosis234-235,240,256-
257. Along these lines, MR activation contributes to AngII-mediated activation of the NADH 
oxidase and superoxide production in the heart and the aorta258-260. Experiments in rats 
revealed, that exogenous aldosterone administration induces p22phox and gp91phox 
expression through an MR-dependent pathway whereas it induces p47phox expression through 
an MR and AT1-receptor dependent pathway254. Apart from these aldosterone-induced changes 
in pro-oxidative systems, it has been shown that MR antagonism increases antioxidant capacity 
by enhancing hepatic antioxidant gluthatione in hypertensive rats236. 
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Beyond its direct pro-oxidative effects on the vasculature, aldosterone enhances the pro-
oxidative effects of AngII that activates the NADPH oxidase in VSMC, monocytes, macrophages 
and endothelial cells67,261. Antagonism of the MR ameliorates AngII-induced superoxide 
production in the heart and the aorta258-260 and attenuates endothelial dysfunction in AngII 
infused rats, either258. Besides its action on AngII effects, aldosterone enhances ACE expression 
in rat aortic endothelial cells and cardiomyocytes262-263 as well as AT1 receptor expression in 
vascular smooth muscle cells264. This suggests a viscous cycle in which AngII, through the AT1 
receptor stimulates the production of aldosterone. This, in turn, leads to an increase of tissue 
ACE activity and an additional increase in AngII-enhanced oxidative stress265. 
An additional mechanism that contributes to aldosterone-induced endothelial dysfunction is the 
exaggerated production of vasoconstrictor factors. Indeed, aldosterone also stimulates 
endothelial dysfunction through activation of COX-2 in normotensive and hypertensive rats. 
Prostacyclin seems to be the main factor contributing to endothelial dysfunction in hypertensive 
rats, whereas other prostanoids such as  prostaglandin E2 and  thromboxane appear to be 
involved in endothelial dysfunction under normotensive conditions239,266. 
Taken together, various studies demonstrated the involvement of aldosterone in the 
development of endothelial dysfunction, on the one hand by decreasing NO bioavailability and 
on the other hand, by enhancing oxidative stress, RAS system activity and prostaglandin 
production. However, the role of the increased aldosterone levels in obesity-induced endothelial 
dysfunction needs further investigations. Especially, the role of the endothelial MR, directly 
exposed to the increased aldosterone in the plasma in obesity, is unknown. Its activation might 
be of major importance since the endothelial MR is directly exposed to circulating aldosterone 
and has been shown to induce signaling pathways that contribute to endothelial dysfunction.  
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3.4 Aim of the study 
Based on the published observations described above, we hypothesized that  
 Increased aldosterone in obesity induces endothelial dysfunction that is 
associated with an enhanced expression of proinflammatory and prooxidative 
factors in aortic endothelial cells 
 The endothelial MR plays a critical role in mediating these effects to the arterial 
wall. 
Our overall strategy is to assess the role of aldosterone in the context of obesity and endothelial 
dysfunction. We will test above hypotheses by fulfilling the following specific aims: 
Aim 1 - Characterize effects of aldosterone/MR on obesity-induced endothelial 
dysfunction and aortic endothelial cell mRNA expression pattern. 
Test the role of aldosterone and MR in obesity-induced endothelial dysfunction and aortic 
endothelial cell mRNA expression using a pharmacological approach. Comparison of 20-weeks 
old C57BL/6 mice kept on a normal-fat (ND), a high-fat diet (HFD) or a high-fat diet containing 
the mineralocorticoid antagonist Eplerenone (HFD EPL) for 14 weeks. 
Aim 2 - Test effects of endothelial MR ablation on obesity-induced endothelial 
dysfunction. 
Assess the role of the endothelial MR in obesity-induced (endogenous aldosterone-mediated) 
endothelial dysfunction by using conditional knockout mice (CreLoxP system). Comparison of 
20-weeks old endothelial cell MR knockout out mice (EC MR KO) and their corresponding 
littermates (MR WT), kept on a ND or HFD for 14 weeks. 
Aim 3 - Determine effects of endothelial MR deletion on aldosterone-induced endothelial 
dysfunction and aortic endothelial cell mRNA expression pattern. 
Investigate the role of the endothelial MR in exogenous aldosterone-induced endothelial 
dysfunction and characterize aortic endothelial cell expression pattern. Comparison of 17-20-
weeks old EC MR KO and MR WT mice, infused with aldosterone for 2 weeks 
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Figure 14. Experimental protocols for in vivo and ex vivo experiments. Concerning aim 1 and 2, in the 
12th week of diet exposure, glucose tolerance tests were performed. After recovery phase of 2 weeks, mice 
were euthanized and blood plasma, cytokine expression in the WAT as well as endothelial function were 
analyzed. In addition, aortic endothelial cells were isolated in Aim I. Except glucose tolerance, all read-outs 
performed in Aim 1, were performed in Aim 3, as well.   
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4 Material and Methods 
4.1 Mouse work 
4.1.1 C57BL/6 mice 
C57BL/6 mice were obtained from The Jackson Laboratory at the age of 6 weeks.  
4.1.2 Conditional endothelial cell MR KO (EC MR KO) mice 
The Cre-loxP system is used to generate conditional knockout animals. This mechanism is a 
special type of site-specific DNA recombination that leads to a tissue- or cell-specific inactivation 
of the gene of interest. The Cre-loxP system was developed in the 1980s267-268 and is patented by 
the American chemical company DuPont.  
It is a specific recombination system that is characterized by the expression of the P1 
bacteriophage enzyme site-specific Cre recombinase (Cyclization Recombination) that 
recognizes and cuts 2 consensus 34 base pair DNA recognitions sites (lox P sites) that flank each 
side of a critical portion of the target gene that should be excised. Since the Cre recombinase and 
the loxP sites are not ubiquitously expressed in the mammalian genome, they must be 
introduced using transgenic mouse technologies. 
To do so, two different transgenic mouse strains are generated. One mouse strain is supposed to 
express the gene of interest flanked with lox P sequences. Therefore, the transgenic sequence is 
constructed from the DNA coding sequence of the gene of interest, surrounded by loxP sites and 
introduced into embryonic stem cells that derived from the inner cell mass of a mouse 
blastocyst. Homologous recombination occurs in the embryonic stem cells leading to 
replacement of the target host gene with the modified gene copy. 
Since the second strain of mice should express the Cre recombinase under the control of a cell-
specific promoter, the coding sequence for Cre, controlled by the desired promoter, is 
introduced into specific cells in late stage embryos of a mouse line.  
After generating the 2 transgenic mouse strains, they are crossbred to produce the Cre-loxP 
strain269. Homologous recombination between the lox P sites occurs in cells/tissue that express 
the Cre recombinase. This leads to a specific gene inactivation in a certain tissue. In cells not 
expressing the Cre recombinase, the promoter is inactive, the gene is preserved and can be 
expressed (Figure16). 
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Figure 16. Cre-loxP system. Crossbreeding of the Cre recombinase transgenic mouse strains with a 
mouse strain, containing lox P sites that flank the gene of interest, results in the removal of the gene of 
interest in all cells expressing the Cre recombinase. All other cell types are unaltered. (Figure adapted 
from270.) 
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To generate endothelial cell-specific MR KO mice we crossed MRflox mice with Tie2Cre mice. The 
MRflox mouse (B6.129P(FVB/N)-Nr3c2tm#Gsc) was kindly provided by the lab of Günther Schütz 
(German Cancer Center, Heidelberg). This mouse possessed a modified MR allele (MRflox allele), 
in which exon 3, encoding the first zinc finger of the MR DNA binding domain, was flanked by 
loxP sites271. Therefore, CreLox recombination should result in deletion of exon 3 and thereby 
prevent binding of MR to the DNA. In turn, MR-dependent transcription should be abolished.  
Mice possessing the Tie2Cre transgene were obtained from the Jackson Laboratory (strain 
name: B6.Cg-Tg(Tek-cre)12Flv/J, stock number: 004128). The Cre recombinase expression in 
these mice was driven under the control of the endothelial-specific receptor tyrosine kinase 
promoter/enhancer (Tie2 or Tek). Tie2 is a receptor tyrosine kinase that binds angiopoietin-1 
and angiopoietin-2 and is expressed in all endothelial cells. This allowed the expression of an 
active Cre recombinase in endothelial cells during embryogenesis and adulthood272. The Tie2 
promotor has also been detected in hematopoietic cells. This might lead to an undesirable Tie2-
Cre recombination in the hematopoietic lineage273 with MR deletion in the corresponding cells. 
To generate endothelial cell-specific MR KO mice (EC MR KO) that were officially named 
B6.129P(FVB/N)-Nr3c2tm4Gsc, MRflox mice were crossbred with Tie2Cre mice. 
In turn, cohorts of MR WT (MRflox/WT) and EC MR KO (MRflox/Tie2Cre) mice were bred by 
crossing MR WT and EC MR KO animals. Due to unspecific activation of Cre recombinase 
expression by the Tie2 promotor in the female germline274, male mice were used to transmit the 
Tie2Cre transgene. This avoided undesirable Cre recombinase activity in cells except from 
endothelial cells and eventually hematopoietic cells. Genotyping was performed to detect the 
presence and of the floxed and deleted alleles271 as well as the presence of the Tie2Cre 
transgene. 
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4.1.3 Genotyping 
4.1.3.1 DNA preparation from the mouse tail 
A 2 mm long piece of mouse tail was incubated in 200 L NID (non ionic detergent) buffer (50 
mM KCl, 10 mM Tris-HCl pH 8.3, 2 mM MgCl2, 0.1mg/ml gelatine, 0.45% Tween20, 0.45% NP40) 
that contained 2 L proteinase K (10 mg/mL). The mixture was incubated overnight at 56°C and 
afterwards inactivated at 96°C for 10 min. 
4.1.3.2 MRflox genotyping 
The PCR reaction mix consisted of 1μl of each primer (10 μM), 0.4μl dNTPs (10 mM), 2μl 
reaction buffer (10x), 0.2 μl  Mg2Cl (50 mM), 12.4 μl ddH2O and 0.2μl DNA polymerase (5 U/μl) 
(Eurobiotaq, Eurobion). 2 μl of DNA isolated from mouse tail was added to the PCR reaction mix. 
Primer (mouse) 5` → 3` 
MRflox fwd CTG GAG ATC TGA ACT CCA GGC T 
MRflox rev TAG AAA CAC TTC GTA AAG TAG AGC T 
 
PCR program:  
Temperature Time Cycles 
96°C 10 min   
95°C  30 sec   
63°C 2 min 35 
72°C 2 min   
72°C 10 min   
4°C ∞   
   
 
The PCR product was mixed with 2 μl loading buffer (10x). 7.5μl of the mixture was loaded on a 
2% agarose gel (100 V, 1 h).  
Size of MR wild-type allele: 285 bp; size of MRflox allele: 335 bp. 
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4.1.3.3 Tie2Cre genotyping 
The PCR reaction mix consisted of 1 μl of each primer (10 μM), 2 μl dNTPs (2.5 mM), 2.5 μl 
reaction buffer (10x), 2.5 μl DMSO, 11.5 μl ddH2O and 0.5 μl DNA polymerase (5 U/μl) (TaKaRa). 
2 μl of DNA isolated from mouse tail was added to the PCR reaction mix. 
Primer (mouse) 5` → 3` 
Tie2Cre fwd GCG GTC TGG CAG TAA AAA CTA 
TieCre rev GTG CAG CAT TGC TGT CAC TT 
IL fwd CTA GGC CAC AGA ATT GAA AGA 
IL rev GTA GGT GGA AAT TCT AGC ATC ATC 
 
PCR program: 
Temperature Time Cycles 
94°C 3 min   
94°C  1 min   
60°C 30 sec 40 
65°C 30 sec   
65°C 5 min   
4°C ∞   
 
The PCR product was mixed with 2 μl loading buffer (10x). 7.5 μl of the mixture was loaded on a 
2% agarose gel (100 V, 1 h). 
Size of Tie2Cre transgene: 100 bp; IL (positive control): 324 bp 
4.1.4. Feeding experiments 
Male animals at the age of 6 weeks were exposed to a normal-fat diet (ND; 10kcal% lard, 1.25% 
total cholesterol, D07121304, Research Diets, New Brunswick, NJ, USA), a high-fat diet (HFD; 
60kcal% lard, 1.25% total cholesterol, D0712305, Research Diets, New Brunswick, NJ, USA) or a 
high-fat diet containing eplerenone (HFD EPL; 60kcal% lard, 1.25% total cholesterol, 
200mg/kg/day Eplerenone, D09012902, Research Diets, New Brunswick, NJ, USA) for 14 weeks. 
The animals were housed in the animal facility of the University of Zürich, Irchel Campus. They 
were exposed to a 12hours day-night-cycle and given free access to water. Weight gain was 
monitored on weekly bases. All animal experiments were approved by the local animal 
committee (animal protocol 2007/175) and performed in accordance with our institutional 
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guidelines. Animals were euthanized with isoflurane (Abbott; Baar, Switzerland) inhalation for 
tissue harvesting.  
4.1.5 In vivo aldosterone infusion 
Alzet osmotic minipumps (Alza, Model 1002) were preloaded with 50 μg/kg/d aldosterone171,275 
or the corresponding vehicle polyethylenglycol 400 (Sigma-Aldrich) and placed in 0.9% saline 
over night before implantation.   
17-20 weeks old male mice were anesthetized using isoflurane inhalation. For the subcutaneous 
implantation of the pump, an incision was made in the skin between the scapulae. Using a 
hemostat, a small pocket was formed by spreading the subcutaneous connective tissue. The 
osmotic pump was inserted into the pocket with the flow moderator pointing away from the 
incision and the skin incision closed by suture. Weight and general health signs were checked 
every day post-operative. After 14 days, mice were euthanized using isoflurane and experiments 
were performed. 
4.1.6 Metabolic cages 
Animals were adapted to metabolic cages (Tecniplast, Buguggiate, Italy) for two times two days 
with breaks in normal cages in between. Animals had free access to ND, HFD and HFD EPL and 
drinking water. Daily, urine output and body weights were measured. Urinary plasma 
aldosterone levels were measured by radioimmunoassay (DRG instruments). 
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4.2 Measurement of plasma parameters 
4.2.1 Glucose tolerance tests 
For glucose tolerance tests, animals were fasted for 14 hours over night. The tip of the tail was 
cut about 0.3-0.5 cm from the end, and then basal fasted glucose was measured from a drop of 
blood emanating from the cut using a standard glucometer (Accu-Check Aviva, Roche). 2 g/kg 
glucose was injected intraperitoneally and blood was drawn after 15, 30 45, 60, 90, 120 and 180 
min from the tail vein to determine blood glucose levels. As a reference value, plasma glucose 
was measured in unfasted state, either. 
4.2.2 Plasma aldosterone and renin measurements  
For determination of plasma aldosterone concentration as well as and renin concentration and 
activity, blood was drawn from the right ventricle after euthanizing the mouse. Plasma was 
transferred into an K2EDTA-coated vial (BD Microtainer #365975), centrifuged (14`000 rpm) at 
4°C for 10minutes, and stored at -80°C. Plasma aldosterone was measured by 
radioimmunoassay (DRG instruments), renin activity and concentration as previously 
decribed276 by our collaborator Jürg Nussberger (University of Lausanne). 
4.3 Analysis of vascular function  
Following euthanasia, abdomen and thorax of the mouse was opened, organs carfully removed 
and aorta was cut proximal to the aortic arch and the diaphragma. Paying attention not to harm 
or overstretch the aorta during the dissection procedure, connective tissue and periadventitial 
fat were carefully removed.  
The vessel was cut into 8 aortic rings (2-3 mm long), of which each was immersed in a 95% 
O2/5% CO2 aerated organ chamber filled with modified Krebs-Ringer bicarbonate solution (118 
mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 1.2 mM NaH2PO4, 1.2 mM Na2SO4, 2.5 mM CaCl2, 25 mM 
NaHCO3, 10 mM glucose, pH to 7.4) and hooked to an isometric force transducer 
(MultiMyograph). 
After equilibration for 60 min, the rings were progressively stretched to 1 g (5 mN). Contraction 
of the rings was assessed by incubation with 80 mM KCl. After 3 min of incubation, KCl was 
flushed off and rings were equilibrated in Krebs-Ringer bicarbonate solution for another 30 min. 
In turn, rings were again stepwise stretched to their optimal passive resting tension (2 g = 10 
mN). Maximal contraction of the rings was assessed by repeated incubation with 80mM KCl for 3 
min. Again, KCl was flushed off and rings were equilibrated in Krebs-Ringer bicarbonate solution 
for 30 min. 
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To assess endothelial function, aortic rings were pre-constricted with norepinephrine (NE), 
whereas the NE-induced contraction was supposed to be 50-70% of the maximal contraction 
induced by KCl. Following the contraction, endothelium-dependent relaxation was induced by 
acetylcholine in a cumulative fashion (Ach, 10−9 to 10−4 M; Sigma-Aldrich) (Figure 17). 
Afterwards, the solution was flushed off and rings were equilibrated for 30 min. 
 
 
Figure 17. Original vascular reactivity trace using an organ chamber. Aortic rings were clamped into 
the organbath, pre-constricted with norepenephrine and afterwards relaxed with acetylcholine (Ach, 10−9 
to 10−4  M) in a cumulative fashion to assess the endothelium-dependent relaxation of the aorta. 
 
To measure endothelium-independent relaxation aortic rings were again pre-constricted with 
NE (30%-70% of KCl-induced contraction) and relaxed by using the external NO-donor sodium 
nitroprussid (SNP, 10−9 to 10−4 M; Sigma-Aldrich) in a cumulative fashion. Relaxations to the 
agonist in aortic rings were given as percent pre-contraction induced by NE.  As a control, 
concentration-dependent contractions were induced by using NE (10−9 to 10−4 M; Sigma-
Aldrich) in a cumulative fashion. Contractions to NE were expressed as percentage of 80 mM 
KCl-induced contractions.  
Whereas 7 aortic rings were treated in parallel as described above, one aortic ring was pre-
incubated with indometacine (5x10-6 M) 30 min before performing each dose-response curve. 
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4.4 Isolation of fresh aortic endothelial cell mRNA  
To isolate fresh mouse aortic endothelial cells, I have established a protocol that allowed me to 
isolate the cells within 70 min after the death of the mouse (Figure 18).  
 
 
Figure 18. Mouse aortic endothelial cell isolation. 
 
Immediately after euthanizing the mouse (Figure 18.1), the midline of the abdomen was incised 
and the thorax was open to expose heart and lung. The right atrium was cut and a whole body-
perfusion from the left ventricle (100 mmHg) was carried using 10 ml ice-cold HBSSCa/Mg free 
(Gibco).  After dissection of the aorta from the aortic arch to the abdominal aorta, removal of 
connective tissue and periadventitial fat, the aortic branches and the aorta distal to the thoracic 
diaphragm were ligated with fiber (Figure 18.2). The aorta was then filled with a 
collagenase/dispase solution (4 mg/ml collagenase/dispase (Roche, #10269638001, 
lot#11730030), 147 pg/ml TLCK (#A17990100 BioChemica), 10 μg/ml DNAseI (Roche, 
#11284932001), 600 ng/ml bovine albumin (Sigma,  #A8412), 6 mM HEPES (Gibco, #15630) 
diluted in 1x HBSSCa2+ Mg2+ free (w phenol red) (Gibco) (Figure 18.3). After filling, the aorta was ligated 
proximal to the heart, excised and incubated for 30 min at 37°C to detach endothelial cells from 
the aortic wall (Figure 18.4).  After the incubation time, cells were flushed out using 10 ml 
HBSSCa/Mg free , centrifuged for 5 min at 1`200 rpm and resuspended in 400 μl of 1 mg/ml bovine 
albumin (Sigma,  #A8412), 10 mM HEPES (Gibco, #15630) diluted in HBSSCa2+ Mg2+ free (w phenol red) 
(Gibco) (Figure 18.5).  
During this procedure, an endothelial cell-specific antibody (purified rat anti mouse CD31, BD 
Pharmingen #557355) was precoupled to Dynabeads (sheep anti-Rat IgG, Dynal, Invitrogen 
#110.35) in a solution consisting of 1 mg/ml bovine albumin (Sigma,  #A8412) and  2 mM EDTA 
in PBS Ca2+ and Mg2+ free (Gibco), pH 7.4 at 4°C for 2.5 h (Figure 18.6).   
4 Materials and Methods 
 
 
- 53 - 
 
The detached aortic cells were purified by incubation of the cell fraction with dynabeads, pre-
coupled to the CD31 antibody, for 20 min at 4°C (Figure 18.7). The purified aortic endothelial 
cells (Figure 18.8) were either stored at -80°C or directly used for RNA isolation using the Micro 
RNeasy Kit (Qiagen #74004). Since a small amount of cells was processed, 20 ng carrier RNA 
(16S and 23S-ribosomal, Roche #206938) was added to the cell lysate before homogenisation.  
A MicroRNA Chip was performed to check concentration and integrity of the RNA.  Good RNA 
quality (RNA integrity number above 6) allowed the amplification of the RNA by using the 
TransPlex Whole Transcriptome Amplification Kit (Sigma-Aldrich, #WTA1) and purification of 
the amplified RNA by using the PCR Purification Kit (Qiagen # 28104). 
4.5 Isolation of tissue RNA   
Harvested tissue was stored for 12 h at 4°C in RNAlater solution (Ambion, #AM7021),.The 
solution was then removed, samples were snap frozen in liquid nitrogen and stored at -80°C 
until further processing. Total RNA isolated from proximal aortae, epididymal, mesenteric and 
periadventitial white adipose tissue was extracted with TRIZOL (Invitrogen, Carlsbad, CA, USA) 
and reverse transcribed using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare, #27-
9264-01). 
4.6 Real-Time RT-PCR 
Real-Time RT-PCR was performed using the SYBR®Green JumpStart™ Taq ReadyMix™ (SIGMA 
#S4438). The reaction mix consisted of 1 μl of each primer (10 μM), 12.5 μl PCR MIX (ready-to-
use), 0.25 μl dye (ready-to-use), 8.25 μl H2O and 2 μl cDNA. For whole organ expression studies, 
10 ng of cDNA and for aortic endothelial cell expression studies, 7.5 ng of cDNA per reaction 
were used. 
Primer (mouse) 5` → 3` 
S12 fwd GAAGCTGCCAAAGCCTTAGA 
S12 rev AACTGCAACCAACCACCTTC 
vWF fwd CAGCATCTCTGTGGTCCTGA 
vWF rev GATGTTGTTGTGGCAAGTGG 
S100A4 fwd GGCCCTGGATGTAATTGTGTC 
S100A4 rev CACCTTCTGGAATGCAGCTTC 
aSMA fwd CTGACAGAGGCACCACTGAA 
aSMA rev CATCTCCAGAGTCCAGCACA 
Hbb-b1 fwd ATGGCCTGAATCACTTGGAC 
Hbb-b1 rev ACGATCATATTGCCCAGGAG 
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  Primer (mouse) 5` → 3` 
MR fwd AAGATCTGCTTGGTGTGTGGAG 
MR rev GCAGGACAGTTCTTTCTCCGAA 
TNFα fwd CCCTCACACTCAGATCATCTTCT 
TNFα rev GCTACGACGTGGGCTACA 
MCP-1 CCCAATGAGTAGGCTGGAGA 
MCP-1 TCTGGACCCATTCCTTCTTG 
CD68 fwd ACATTGTATTCCACCGCCAT 
CD68 rev GAGGTTGTGACGGTACCCAT 
C1-inhibitor fwd TGGACCAGGACGCAGCTGACA 
C1-inhibitor 1 rev TGGGTGCTGTGGCTGGTAGC 
ICAM-1 fwd GTCCGCTGTGCTTTGAGAAC 
ICAM-1 rev GCACCGTGAATGTGATCTCC 
VCAM-1 fwd ATATGACATGCTTGAGCCAGGGC 
VCAM-1 rev GTGTCTCCTTCTTTGACACTCTC 
eNOS fwd CTGGGTTTAGGGCTGTGCGGC 
eNOS rev CCAGGGATCCCAAGCAGCGTC 
Prostacyclin Synthase fwd GGCTCCTTGTCAGCGGGGGATA 
Prostacyclin Synthase rev CCGCGAGGGCTTCCGGATTC 
COX-1 fwd CTTCTCCACGATCTGGCTTC 
COX-1 rev GCTCGCAGGAAATAGCCACTC 
COX-2 fwd GCTGTACAAGCAGTGGCAAA 
COX-2 rev CCCCAAAGATAGCATCTGGA 
SOD-1 fwd TACTGATGGACGTGGAACCC 
SOD-1 rev GAACCATCCACTTCGAGCA 
SOD-3 fwd ATGGCTGAGGTTCTCTGCAC 
SOD-3 rev ACTCAGAGGCTCTTCCTCCG 
Catalase fwd ATGACAACCAGGGTGGTGCCCC 
Catalase rev CCTGGATGCGGGCCCATAGT 
p22phox fwd GTGTGAAACGTCCAGCAGT 
p22phox rev GTCATGGGGCAGATCGAGT 
p47phox fwd TCCTCTTCAACAGCAGCGTA 
p47phox rev CTATCTGGAGCCCCTTGACA 
p40phox fwd CCTGCCCACATTGCCAGCCA 
p40phox rev AGACCGGCAGGCTCAGGAGG 
Rac-1 fwd TTTTCCCCAGCTTTGGGTGGTGG 
Rac-1 rev TGGTCGTGTAACTGATGAGCAGGC 
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qPCR program: 
Temperature Time Cycles 
95°C 10min   
95°C 30 sec   
55°C 1 min 40 
72°C 30 sec   
95°C 1 min   
55°C 30 sec   
95°C 30sec   
4°C ∞   
 
The expression of mRNA of genes of interest was calculated relative to the ribosomal S12 as 
reference housekeeping gene. Relative expression ratios were estimated as R = (2(Ct(reference) 
– Ct(test)). Ct: cycle number at the threshold, test: tested mRNAs (e.g. MR). 
4.7 Immunofluorescence staining of von Willebrand factor 
(vWF) 
Aortae were embedded in OCT and stored at -80°C. 0.4 μm thick slices were cut using a Cryostat 
and mounted on a microscope slide. After air drying for 15 min, slices were washed with PBS 
and fixed with 4% paraformaldehyde (PFA). Cryosections were blocked with 3% BSA / 0.1% 
Triton-X100 for 30 min and incubated at room temperature for 90 min with the primary 
antibody against vWF (rabbit anti-human) diluted 1:400 in 3% BSA / 0.1% Triton-X100. After 
washing, slices were incubated for 30 min at room temperature with conjugated secondary 
antibody (Texas Red, 594 goat-anti-rabbit IgG, Invitrogen, USA) diluted 1:500 in 3% BSA/0.1% 
Triton-X100. Slices were mounted with DAPI-fluorescence mounting media (Vectashield, Vector 
Laboratories, Inc., Burlingame, CA 94010) and images acquired using the Nikon Eclipse TE3000 
inverted fluorescence microscope (Nikon AG Küsnacht, Switzerland) equipped with a DS-5M 
Standard CCD camera (Nikon) and the NIS-Elements software (Nikon). Images were further 
processed using Photoshop 7 (Adobe, San Jose, USA). 
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4.8 FACS analyses 
Isolated aortic endothelial cells were incubated with a 0.5% BSA-PBS for blocking. After that, 
cells were incubated with a biotinylated primary antibody that recognizes Isolectin B4 
(Vectorlab #B-1205) diluted 1:50 in 0.5% BSA-PBS for 30 min. After washing with PBS, cells 
were incubated with a secondary antibody, namely FITC-conjugated Streptavidine (eBiosience 
#11-4317-87) diluted 1:50 in 0.5% BSA-PBS for 30 min. Flow cytometry analyses were 
performed using the FACSCanto. Analyses were performed using the FlowJo software. 
4.9 Statistics 
Data were expressed as means ± standard error of the mean (SEM). Calculations were carried 
out using Microsoft Excel, while the graphs were created using GraphPad Prism™ Version 5.0 
(GraphPad Inc.). Significance was tested with GraphPad Prism™ using students T-Test unpaired 
or one-way ANOVA. Statistical significance was accepted at P < 0.05. 
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5 Results 
5.1 MR antagonism attenuates obesity-induced endothelial 
dysfunction by modulating inflammation and enzymes, 
associated with prostanoid and ROS production  
5.1.1 MR antagonism attenuates obesity-associated glucose 
intolerance 
To address the contribution of endogenous aldosterone in the development of endothelial 
function, we induced obesity by exposing 6-week-old male C57BL/6 mice to a high-fat diet in the 
absence (HFD) or presence of eplerenone (HFD EPL) for 14 weeks. Control mice were fed a 
normal diet (ND). Compared to lean mice, HFD feeding resulted in a significant increase in 
relative body weight and total epididymal WAT, an established marker for obesity in male mice 
(Figure 19 A, B). Feeding HFD EPL led to the same weight gain in mice as feeding with HFD in 
absence of EPL (Figure 19A). Therefore, eplerenone has no effect on the degree of diet-induced 
obesity in mice.  
 
Figure 19. Increased weight gain in lean and diet-induced obese C57BL/6 mice with or without 
pharmacological MR antagonism. C57BL/6 mice were treated with ND, HFD or HFD EPL. After 14 
weeks (A) relative weight gain and (B) epididymal fat pad mass were measured. Data are mean±SEM; 
n=6–10. *P<0.05 for ND vs HFD; $P<0.05 for ND vs HFD EPL. 
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Since eplerenone can exert beneficial effects on insulin resistance216 we assessed the metabolic 
state of the ND, HFD and HFD EPL fed mice, 12 weeks after beginning of diet exposure. This 
allowed the mice to recover for 2 week after the glucose tolerance tests, before using them for 
the actual primary end-point experiments. Blood glucose was similar in all 3 groups of mice in 
the non-fasted state (Figure 20A), whereas glucose levels were significantly increased in obese 
fasted mice (Figure 20B). EPL treatment of obese mice reduced this hyperglycemic state, non-
significantly (Figure 20B). To characterize the glucose tolerance more in detail, we performed 
blood glucose tolerance tests (Figure 20C). Indeed, we observed an impaired glucose tolerance 
in obese mice. Eplerenone treatment in obesity restored the impaired glucose tolerance 180 min 
after the glucose load. We could conclude that EPL attenuates hyperglycemia as well as blood 
glucose tolerance in obesity. 
 
Figure 20. Impaired glucose tolerance in diet-induced obese C57BL/6 mice is attenuated by MR 
antagonism. C57BL/6 mice were treated with ND, HFD or HFD EPL for 14 weeks. After 12 weeks of diet 
blood glucose levels were determined (A) under fed state (B) after fasting for 16h over night and (C) in a 
time course after injection of 2 g glucose/kg bodyweight. Data are mean±SEM; n=6–10. *P<0.05 for ND vs 
HFD; #P<0.05 for HFD vs HFD EPL. 
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5.1.2 Increased plasma aldosterone concentration in obesity 
To characterize the putative activation of components of the RAAS in our mouse model of 
obesity, we assessed renin concentration and activity as well as plasma and urine aldosterone 
levels. Considering the circadian alterations of the RAAS277-278, we decided to take the mouse 
plasma always at the same time of the day, at 9 a.m. Renin concentrations and activity remained 
unaltered in mice fed a HFD in absence or presence of EPL compared to lean mice (Figure 21A, 
B), whereas aldosterone concentrations were significantly higher in obesity (Figure 21C). These 
observations indicate that obesity increases plasma aldosterone in a renin-independent way. 
Additionally, we observed an even further increase in plasma aldosterone when EPL was 
administered. Since an unspecific cross-reaction of the Aldosterone-RIA with the EPL in the 
mouse plasma could not be excluded, we performed an additional experiment to test if the 
increased aldosterone concentration in the HFD EPL group is a false positive result.  It has been 
shown in humans that an oral single dose of 100 mg EPL results in maximal 1.72 μg/ml EPL in 
the plasma279-280. Since we administered 8 mg EPL/day via diet to our mice, we expected EPL in 
the concentration in the plasma approximately 96`000 ng/l. Therefore, we administered either 
105 ng/l or 107 ng/l EPL to mouse plasma and measured aldosterone concentration. In fact, we 
could show that aldosterone levels are not falsely increased in mouse plasma, containing EPL 
(Figure 21D). We conclude that the Aldosterone-RIA recognizes aldosterone specifically and that 
EPL treatment increases aldosterone release in obesity, most likely due to a blocked MR-
dependent regulatory feedback loop. 
 
.  
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Figure 21. Unaltered renin levels and increased plasma aldosterone levels in diet-induced obese 
C57BL/6 mice. C57BL/6 mice on ND, HFD and HFD EPL (n=8-10) were analyzed concerning (A) plasma 
renin concentration, (B) plasma renin activity and (C) plasma aldosterone concentration. (D) Aldosterone 
concentrations were measured in plasma of C57BL/6 containing 100`000 ng/l or 10`000`000 ng/l EPL. 
Data are mean±SEM; n=6–10. *P<0.05 for ND vs HFD; #P<0.05 for HFD vs HFD EPL;$P<0.05 for ND vs HFD 
EPL. 
To characterize the release of aldosterone in obesity in more detail, we performed experiments 
with metabolic cages and sampled the urine of ND and HFD fed mice every 24 hours. 
Surprisingly, we observed decrease aldosterone levels in the urine of obese mice (Figure 22A). 
In order to exclude, that the decreased aldosterone levels in obesity arise a faster degradation of 
aldosterone in its tetra-hydro-from, which could not be detected by the Aldosterone-RIA, we 
tried to assess the activity of the aldosterone-degrading reductase in an indirect manner.  
Aldosterone is degraded to its dehydro- as well as tetrahydro-metabolites by the same 5β-
reductase as corticosterone. Since our collaborator Brigitte Frey (Inselspital, Bern) was able to 
assess the concentration of the corticosterone degradation products tetrahydro-corticosterone 
(TBH), 5α-tetrahydro-corticosterone (5α-THB) and 11-dehydro-corticosterone (THA) in the 
urine of the mice (Figure 22B), we hoped to receive information about the activity of the 5β-
reductase. Unluckily, the amount of urine we had available was too small to measure the 
degradation products in each sample. Therefore, we are not able to explain the reason for the 
decreased urinary aldosterone levels in obesity.  
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Figure  22. Decreased urinary aldosterone and corticosterone metabolites in diet-induced obese 
C57BL/6 mice. C57BL/6 mice on ND, HFD were analyzed concerning (A) urinary alosteron/creatinine and 
(B) corticosterone degradation products tetrahydro-corticosterone (TBH), 5α-tetrahydro-corticosterone 
(5α-THB) and 11-dehydro-corticosterone (THA). Data are mean±SEM; n=1–5. *P<0.05 for ND vs HFD. 
In a next step, we decided to investigate whether MR mRNA expression levels were changed in 
aortic or in epididymal WAT upon of ND, HFD and HFD EPL feeding, respectively. Compared to 
lean mice, MR mRNA expression tended to be increased in obese mice in the aortae as well as in 
the epididymal and mesenteric WAT. EPL HFD treatment further increased MR mRNA 
expression in these tissues (Figure 23A, B). The observations concerning increased plasma 
aldosterone as well as tissue MR mRNA expression suggest an important role of aldosterone-
induced MR signaling in obesity. 
 
 
Figure 23. Tissue MR expression is increased in obesity and further elevated by MR antagonism. 
C57BL/6 mice on ND, HFD and HFD EPL (n=8-10) were analyzed concerning (A) MR mRNA in aortic 
lysates and (B) MR mRNA in epididymal and mesenteric fat pads, standardized to S12 and normalized to 
ND. Data are mean±SEM; n=6–10. *P<0.05 for ND vs HFD; $P<0.05 for ND vs HFD EPL. 
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5.1.3 MR antagonism attenuates obesity-induced proinflammatory 
changes in WAT  
It has been demonstrated, that MR antagonism can reverse proinflammatory cytokine 
expression in the adipose tissue of genetically obese mice219. Along that line, we investigated 
whether the inflammatory state in diet-induced obese mice was altered by MR antagonism, 
either. To do so, we isolated the epididymal, mesenteric and periadventitial fat pads of C57BL/6 
mice on ND, HFD or HFD EPL and extracted mRNA for qPCR analyses. 
The epididymal WAT of obese animals showed elevated mRNA levels of macrophage-specific 
glycoprotein CD68, suggesting an increased macrophage infiltration in this tissue (Figure 24A). 
Moreover, mRNA levels of proinflammatory cytokines such as TNF-α and MCP-1 were increased 
in the epididymal and mesenteric WAT of obese mice compared with lean control mice (Figure 
24A, B). Chronic treatment with EPL markedly reduced mRNA levels of TNF-α and MCP-1 in the 
epididymal and mesenteric, as well as CD68 mRNA expression in the epididymal WAT (Figure 
24A, B). In addition, we observed an increased expression of CD68 in the periadventitial fat of 
obese mice, but no change upon EPL administration (Figure 24C). Due to a marked variation of 
results, a regulation of MCP-1 under HFD conditions in the periadventitial white adipose tissue 
is doubtful. Furthermore, TNF-α mRNA expression remained unaltered in this fat pad. 
These data suggest that obesity-induced proinflammatory changes are most pronounced in the 
epididymal WAT. These inflammatory changes are diminished by MR antagonism in the 
epididymal, mesenteric and periadventitial WAT.  
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Figure 24. Obesity-induced proinflammatory mRNA expression in white adipose tissue is 
attenuated by MR antagonism. mRNA levels (A) epididymal fat pad, (B) mesenteric fat pad and (C) 
periadventitial fat pad in C57BL/6 mice on ND, HFD and HFD EPL standardized to S12 and normalized to 
ND levels for CD68, MCP-1, and TNF-α. Data are mean±SEM; n=6–8.*P<0.05 for ND vs HFD; #P<0.05 for 
HFD vs HFD EPL. 
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5.1.4 MR antagonism reverses obesity-induced endothelial 
dysfunction  
The involvement of MR activation in the development of several cardiovascular diseases has 
been demonstrated in various studies234,281-282. Since endothelial dysfunction is an initial step in 
the development of cardiovascular diseases, we decided to investigate the effect of increased 
aldosterone levels in obesity on endothelial function. To do so, we performed organ chamber 
experiments using C57BL/6 mice on ND, HFD and HFD EPL, respectively (Figure 25). 
Endothelium-dependent relaxations to acetylcholine were blunted in aortae of obese mice 
starting at a concentration of 3x10-6  M acetylcholine and reaching a maximal relaxation at 10-4 M 
acetylcholine, proving pronounced endothelial dysfunction in obesity. Interestingly, chronic EPL 
treatment in obese mice restored endothelium-dependent relaxation completely back to levels 
of a ND (Figure 25A). Endothelium-independent relaxations, assessed by administration of the 
external NO donor sodium nitroprussid (SNP), were unaffected by obesity and reached a 
maximal relaxation in all 3 groups at 10-4 M SNP (Figure 25B). Furthermore, contractions to NE 
were unaffected by obesity and MR antagonism, respectively (Figure 25C).  
These data suggest profound beneficial effects of MR antagonism on obesity-induced endothelial 
dysfunction. 
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Figure 25. MR antagonism restores obesity-induced endothelial dysfunction. Endothelial function 
studies in C57BL/6 mice on ND, HFD and HFD EPL. The response of aortic rings preconstricted with 
norepinephrine in increasing concentrations of (A) endothelium-dependent vasodilator acetylcholine 
(Ach) (B) and endothelium-independent vasodilator SNP. % Relaxation = % precontraction to 
norepinephrine. (C) Contraction of aortic rings at increasing norepinephrine concentrations. % 
Contraction = % of contraction to 80 mM KCl. Data are mean±SEM; n=8–10. *P<0.05 for ND vs HFD; 
#P<0.05 for HFD vs HFD EPL. 
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5.1.5 MR antagonism diminishes obesity-induced expression of 
endothelial inflammation, prostanoid- and ROS-modulating 
enzymes  
Since we could show that MR antagonism reverses obesity-induced endothelial dysfunction, we 
were wondering which mediators and signalling molecules were increased or downregulated in 
aortic endothelial cells, contributing to the improvement of endothelial function in obesity. 
Hence, we decided to develop a method to isolate fresh aortic endothelial cell mRNA from 
C57BL/6 mice exposed to ND, HFD, HFD EPL (Materials and Methods; Figure 18) within 70 min 
after euthanasia of the mice.  
In short, the aortic endothelial cell isolation procedure was divided into two main steps. The first 
one comprised the dissection and filling of the aorta with a 0.4% Collagenase/Dispase solution, 
followed by an incubation step for 30 min at 37°C to detach the endothelial cells from the vessel 
wall. The successful secession of aortic endothelial cells from the vessel lumen could be 
confirmed by immunofluorescence staining for the endothelial cell marker vWF. In a 
Collagenase/Dispase-untreated aorta, the vWF staining was clearly visible at the luminal 
endothelial cell layer (Figure 26A). Treatment of the aorta with the Collagenase/Dispase 
solution resulted in a negative vWF staining (Figure 26B), indicating the successful removal of 
endothelial cells. 
 
Figure 26. Detachment of aortic endothelial cells from vessel wall after Collagenase/ Dispase 
treatment. Immunofluorescence staining using a monoclonal anti-vWF antibody (1:400). (A) 
Collagenase/Dispase-untreated aorta and (B) Collagenase/Dispase-treated aorta. 
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The second main step in the aortic endothelial cell isolation procedure consisted of the 
purification of the isolated cells. Hence, the isolated cells were mixed with magnetic beads that 
were pre-coupled to an endothelial cell specific anti-CD31 antibody. After 20min of incubation, 
unbound cells were discarded, whereas all cells that bound to the beads-antibody-complex 
where supposed to be endothelial cells.  
To confirm the purity of the aortic endothelial cells, the isolated cell fraction was stained for flow 
cytometry analyses. In turn, we used an isolectin B4-recognizing, biotinylated antibody that has 
been described to recognize murine endothelial cells, specifically283. We could show that the 
isolated cells express a relatively high amount of isolectin B4, suggesting that the isolated cells 
are indeed endothelial cells (Figure 27A). To verify this result, we compared the mRNA 
expression levels of the isolated cells with whole aortic lysate concerning endothelial cell 
marker vWF284, smooth-muscle cell and fibroblast marker S100A4285-286 and the hemoglobin, 
beta adult major chain (Hbb-b1) of erythrocyte (Figure 27B). The vWF mRNA was nearly 20-fold 
higher expressed in the isolated cell fraction in comparison to whole aortic tissue. In contrast, 
the markers of fibroblast and erythrocyte were low in isolated cells, thereby underlining the 
purity of our freshly isolated endothelial cells. 
 
Figure 27. Isolation of murine aortic endothelial cells. (A) Flow cytometry analyses of aortic 
endothelial cells stained with biotinylated isolectin B4 as primary antibody and FITC-conjugated 
streptavidine as secondary antibody. (B) Aortic tissue and aortic endothelial cells isolated from C57BL/6 
mice. mRNA levels of endothelial cell marker vWF, fibroblast and smooth muscle cell marker S100A4, and 
erythrocyte marker Hbb-b1 standardized to S12. Data are mean±SEM; n=6–10. *P<0.05 for isolated EC vs 
aortic tissue. 
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Since we could show, that we were able to isolate pure aortic endothelial cells from C57BL/6 
mice exposed to ND, HFD and HFD EPL, we tested the expression of proinflammatory molecules, 
thereby investigating the influence of both HFD and HFD EPL on mRNA expression patterns. 
ICAM-1 mRNA showed a non-significant increase with obesity and a marked decrease by 
eplerenone in obese mice; VCAM-1 expression increased upon HFD exposure but remained 
unaltered with eplerenone. Moreover, expression of the C1-inhibitor and MR was induced by 
eplerenone in obesity (Figure 28A). Interestingly, we could observe a slight increase of MR 
mRNA expression under HFD and an even higher increase upon EPL treatment (Figure 28A); the 
same MR mRNA pattern as observed in whole aortic tissue and WAT (Figure 23). 
A closer look on mediators involved in the development of endothelial dysfunction revealed that 
prostacyclin synthase and COX-1 mRNA were upregulated in obesity, whereas COX-2 expression 
was unaltered (Figure 28B). Furthermore, eNOS mRNA expression increased upon HFD EPL 
exposure compared with the ND (Figure 28B).   
Taken together, we observed an obesity-induced expression of proinflammatory mediators in 
obesity that was partially attenuated by MR antagonism. In addition, we could show that obesity 
enhances the expression of enzymes that are involved in the generation of vasoconstricting 
prostanoids and that MR antagonism increases the expression of eNOS in obesity.  
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Figure 28. Some obesity-induced proinflammatory and prostanoid-related changes are alterd by 
MR antagonism in aortic endothelial cells. Aortic endothelial cell mRNA levels in C57BL/6 mice on ND, 
HFD, HFD EPL (EPL) after 14 weeks standardized to S12 (A) ICAM-1, VCAM-1, C1-inhibitor, MR, (B) 
prostacyclin-synthase, COX-1, COX-2, eNOS. Data are mean±SEM; n=9-12. *P<0.05 for ND vs HFD; #P<0.05 
for HFD vs HFD EPL; $P<0.05 for ND vs HFD EPL. 
Given the link of aldosterone to oxidative stress251,254,257, we decided to analyze the isolated 
aortic endothelial cell mRNA from ND, HFD and HFD EPL fed mice concerning expression levels 
of antioxidant systems and NADPH-oxidase subunits. Regarding antioxidant systems, we found 
levels of SOD-1 and SOD-3 increased under ND and HFD EPL conditions in comparison to HFD; 
catalase expression was not altered significantly (Figure 29A). In addition, we found that mRNA 
expression of the NADPH-oxidase subunits p22phox, p47phox, and gp91phox was not affected 
by obesity. However, EPL treatment significantly attenuated the expression of p22phox and 
p47phox (Figure 29B). On the other hand, obesity increased endothelial expression of p40phox 
and Rac-1 that was attenuated by EPL (Figure 29B). Taken together, we observed an obesity-
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induced oxidative stress-associated mRNA expression profile in aortic endothelial cells that was 
partially restored by MR antagonism. 
 
Figure 29. Obesity-induced oxidative stress is attenuated by MR antagonism in aortic endothelial 
cells. Aortic endothelial cell mRNA levels in C57BL/6mice on ND, HFD, HFD EPL (EPL) after 14 weeks 
standardized to S12 (A) SOD-1, SOD-3, catalase,(B) p22phox, p47phox,  gp91phox, p40phox, Rac-1. Data 
are mean±SEM; n=9-12. *P<0.05 for ND vs HFD; #P<0.05 for HFD vs HFD EPL. 
Together with the increased expression of inflammatory markers and prostanoid-generating 
enzymes, the enhanced expression of endothelial oxidative stress-related systems might 
contribute to the development of endothelial dysfunction in obesity. MR antagonism seems to 
attenuate this protective EC expression profile, being therefore responsible for improved 
endothelial function in obesity.   
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5.2 Endothelial MR ablation prevents obesity-induced 
endothelial dysfunction  
5.2.1 Ablation of the endothelial MR – generating EC MR KO mice 
In the previous section we were able to show a beneficial effect of MR antagonism on obesity 
induced-endothelial dysfunction as well as on inflammatory, prostanoid- and oxidative stress-
related endothelial cell mRNA expression pattern.  
In order to characterize the obesity-induced changes in the endothelium in more detail, we 
generated mice lacking the MR in endothelial cells (EC MR KO) by crossing floxed MR mice with 
Tie2-Cre mice.  To verify the successful action of the CreLoxP system in this context, we 
performed qPCR analyses of aortic endothelial cell DNA, isolated from MR WT and EC MR KO 
mice, checking the successful excision of the MR. Indeed, we could show that the MR knock out 
appeared to be 92.8% (±3.2%) efficient in EC MR KO mice in comparison to their MR WT 
littermates (Figure 30A).  
In order to determine the specificity of the EC MR KO, we assessed MR expression the whole 
aortic tissue, peritoneal macrophages and epididymal WAT (Figure 30B). Whereas MR 
expression was almost unaltered in whole aortic tissue and WAT, the MR seems to be ablated in 
peritoneal macrophages. This phenomenon has been already reported previously in 
hematopoietic cells287  and is due to an unspecific activation of the Tie2 promoter in these cells. 
 
Figure 30. MR ablation in EC MR KO mice. MR DNA levels of (A) endothelial cell (n=8), (B) peritoneal 
macrophages, epididymal fat pad and whole aortic lysates (n=6) in MR WT and EC MR KO mice 
standardized to S12, *P<0.05. Values are mean ± SEM. 
  
5 Results 
 
 
- 72 - 
 
5.2.2 Endothelial MR ablation has no effect on obesity-associated 
glucose intolerance 
To elucidate the role of the endothelial MR in diet-induced obesity, we exposed EC MR KO mice 
and their corresponding MR WT littermates to a ND or HFD for 14 weeks. Relative weight gain 
and epididymal fat mass did not differ between EC MR KO and MR WT animals neither under ND 
nor under HFD conditions (Figure 31A, B).  
 
Figure 31. Similar high-fat diet induced increase in weight gain in lean and diet-induced obese MR 
WT and EC MR KO mice. MR WT and EC MR KO mice were treated with ND and HFD for 14 weeks. After 
14 weeks (A) relative weight gain and (B) epididymal fat pad mass were measured. Data are mean±SEM; 
n=6–8.*P<0.05 for MR WT ND vs MR WT HFD; #P<0.05 for EC MR KO ND vs EC MR KO HFD. 
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To check whether endothelial cell MR ablation affects obesity-induced hyperglycemia, we tested 
blood glucose of MR WT and EC MR KO mice after 12 weeks of ND or HFD. We found no 
difference in fed and fasted blood glucose in MR WT and EC MR KO mice, neither under ND nor 
under HFD (Figure 32A, B). Glucose tolerance tests revealed an impaired glucose tolerance in 
both obese MR WT and EC MR KO, respectively (Figure 32C). Since glucose tolerance seemed to 
be impaired to the same extent in MR WT and EC MR KO, we concluded that EC MR plays no role 
in obesity-associated diabetes. 
 
 
 
Figure 32.  Glucose tolerance in lean and diet-induced obese MR WT and EC MR KO mice.  MR WT 
and ECMR KO mice were treated with ND and HFD for 14 weeks. After 12 weeks of HFD, blood glucose was 
determined (A) under fed state (B) after fasting for 16 h over night and (C) in a time course after injection 
of 2 g glucose/kg body weight. Data are mean±SEM; n=6–8.&P<0.05 for MR WT HFD vs MR WT ND; 
#P<0.05 for EC MR KO ND vs EC MR KO HFD.  
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5.2.3 Endothelial MR ablation has no effect on obesity-induced 
increase of plasma aldosterone  
To test whether endothelial MR deletion affects aldosterone generation or degradation, we 
measured aldosterone concentration in the plasma of MR WT mice and EC MR KO after 14 weeks 
of ND or HFD. Both obese MR WT mice and EC MR KO showed a similar increase in plasma 
aldosterone (Figure 33A). Therefore, endothelial MR has no relevant effect on aldosterone 
turnover. 
MR mRNA analysis of whole aortic tissue isolated from MR WT mice and EC MR KO revealed that 
the MR mRNA expression in wild-type and KO mice is similar in the whole vessel. Furthermore, 
obesity did not enhance MR mRNA expression in MR WT and EC MR KO, respectively (Figure 
33B). We observed a similar MR mRNA expression pattern in the aorta and in the epididymal 
WAT (Figure 33C). 
 
Figure 33. Plasma aldosterone levels in lean and diet-induced obese MR WT and EC MR KO mice. MR 
WT and EC MR KO mice on ND or HFD were analyzed concerning (A) plasma aldosterone levels (B) MR 
mRNA of aorta (C) epididymal fat pads, standardized to S12 and normalized to ND. Data are mean±SEM; 
n=6-8.*P<0.05 for MR WT ND vs MR WT HFD; #P<0.05 for EC MR KO ND vs EC MR KO HFD. 
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5.2.4 Endothelial MR ablation has no effect on obesity-induced 
proinflammatory changes in the WAT 
In a next step, we wanted to test the effect of the endothelial MR deletion on proinflammatory 
cytokine expression in the WAT. In previous experiments of diet-induced obesity we observed 
the most pronounced anti-inflammatory effects by MR blockade in the epididymal fat pad 
(Figure 6A). Therefore, we decided to test, if an endothelial MR deletion is sufficient to reverse 
proinflammatory changes in the epididymal WAT in obesity. 
We exposed MR WT and EC MR KO mice to a ND or HFD for 14 weeks and analyzed the 
epididymal WAT concerning the expression of proinflammatory markers. TNF-α, MCP-1 and the 
macrophage marker CD68 mRNA levels increased significantly to the same extent in MR WT and 
EC MR KO mice upon HFD exposure (Figure 34).  These data suggest that endothelial MR 
deletion has no effect on the pro-inflammatory state of the WAT. Moreover, these findings imply 
that the MR deletion in macrophages of the WAT has no relevant effect on the inflammatory 
profile of the WAT. 
 
Figure 34. Obesity-induced and aldosterone-induced proinflammatory changes in white adipose 
tissue are unaltered by endothelial MR KO. mRNA levels of epididymal fat pad in MR WT and EC MR KO 
mice on ND or HFD were standardized to S12 and normalized to ND levels for CD68, TNF-α, MCP-1. Data 
are mean±SEM; n=6-8.*P<0.05 for MR  WT ND vs MR WT HFD; #P<0.05 for EC MR KO ND vs EC MR KO 
HFD. 
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5.2.5. Endothelial MR ablation prevents obesity-induced 
impairment of vasodilation 
To determine whether obesity-induced endothelial dysfunction was mediated by the endothelial 
MR, we exposed WT and EC MR KO mice to a ND or HFD for 14 weeks and performed organ 
chamber experiments. Compared with lean controls, obese MR WT mice demonstrated a 
significant impairment of endothelium-dependent vasodilation starting at 10-7 M acetylcholine; 
strikingly, we could show that a MR deletion in endothelial cells completely abolished the 
endothelial dysfunction (Figure 35A). Endothelial-independent SNP-induced relaxation (Figure 
35B) and contractions induced by norepinephrine (Figure 35C) were similar in MR WT and EC 
MR KO on ND or HFD, respectively. 
Therefore, we conclude that the endothelial MR plays a crucial role in the development of 
obesity-induced endothelial dysfunction. 
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Figure 35. Obesity-induced endothelial dysfunction is prevented in EC MR KO mice. Endothelial 
function studies in MR WT and EC MR KO mice on ND and HFD: The response of aortic rings preconstricted 
with norepinephrine to increasing concentrations of (A) endothelium-dependent vasodilator 
acetylcholine (Ach) (B) and endothelium-independent vasodilator SNP. % Relaxation = % precontraction 
to norepinephrine. (C) Contraction of aortic rings at increasing norepinephrine concentrations. % 
Contraction = % of contraction to 80 mM KCl. Data are mean±SEM; n=6–8. *P<0.05 for MR WT ND vs MR 
WT HFD; #P<0.05 for MR WT HFD vs EC MR KO HFD; $P<0.05 for MR WT HFD vs EC MR KO ND.  
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5.3 Endothelial MR ablation attenuates aldosterone-induced 
endothelial dysfunction by modulating enzymes, associated 
with prostanoid and ROS production 
Subsequently, we tested whether the effects in obesity associated with high endogenous 
aldosterone could be mimicked with high exogenous aldosterone alone without obesity. 
To do so, we implanted osmotic minipumps in lean MR WT mice and EC MR KO mice containing 
aldosterone or vehicle. Aldosterone infusion for 2 weeks increased plasma aldosterone to the 
same extent in both MR WT and EC MR KO mice (Figure 36). Since we were able to obtain a 
similar increase of plasma aldosterone by exogenous administration as obesity induces 
aldosterone production endogenously, we could dissect the role of increased aldosterone 
without the additional metabolic and inflammatory changes conferred by obesity. 
 
Figure 36. Plasma aldosterone levels in vehicle- or aldosterone-infused lean MR WT and EC MR KO 
mice. MR WT and EC MR KO mice on ND or HFD and vehicle-, or aldosterone-infused mice were analyzed 
concerning plasma aldosterone levels. Data are mean±SEM; n=6-8.*P<0.05 for MR WT vehicle vs MR WT 
aldo; #P<0.05 for EC MR KO vehicle vs EC MR KO aldo. 
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5.3.1 Endothelial MR ablation and COX inhibition restore 
aldosterone-induced impaired vasodilation 
To determine whether obesity-induced, endothelial MR-mediated endothelial dysfunction was 
induced by aldosterone, MR-dependent or independent pathways we tested endothelial function 
of aldosterone- or vehicle-infused MR WT and EC MR KO mice. Infusion of aldosterone for 2 
weeks blunted endothelial function in concentrations of acetylcholine above 10-7mol/l. Indeed, 
deletion of the endothelial MR attenuates aldosterone-induced endothelial dysfunction, 
completely (Figure 37A). Endothelium-independent relaxation by SNP (Figure 19B) and 
contractions induced by norepinephrine (Figure 37C) were similar in all groups.  
Since we observed increased mRNA expression of COX-1 and prostaglandin synthase in aortic 
endothelial cells in obesity (Figure 28B), we tested the effects of a COX-1/COX-2 inhibition on 
exogenous aldosterone-induced endothelial dysfunction. We could clearly show that inhibition 
of COX by indometacin normalizes endothelial function in aldosterone-infused mice to the same 
extent as endothelial MR deletion (Figure 37D).  
We conclude from these results, that the endothelial MR plays a crucial role in obesity- as well as 
in aldosterone-induced endothelial dysfunction. Since we could show that COX seems to 
contribute to aldosterone induced-endothelial dysfunction, we suggest that the endothelial MR 
induces COX-1 expression.   
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Figure 37. Aldosterone-induced endothelial dysfunction is prevented in lean EC MR KO mice and 
upon COX inhibition, respectively. Endothelial function studies in MR WT and EC MR KO mice after 
aldosterone or vehicle infusion: The response of aortic rings preconstricted with norepinephrine to 
increasing concentrations of (A) endothelium-dependent vasodilator acetylcholine (Ach), (B) 
endothelium-dependent vasodilator Ach and preincubated with indometacine and (C) endothelium-
independent vasodilator SNP. % Relaxation = % precontraction to norepinephrine. (D) Contraction of 
aortic rings at increasing norepinephrine concentrations. % Contraction = % of contraction to 80 mM KCl. 
Data are mean±SEM; n=6–8. *P<0.05forMR WT ND vs MR WT HFD; #P<0.05 for MR WT HFD vs ECMR KO 
HFD; $P<0.05 for MR WT HFD vs EC MR KO ND.  
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5.3.2 Exogenous aldosterone infusion does not induce the 
expression of proinflammatory markers in the WAT 
To test the effects of endothelial MR ablation on aldosterone-induced inflammation in the WAT, 
we infused MR WT and EC MR KO mice with aldosterone for 2 weeks and tested expression 
proinflammatory markers in the epididymal WAT. Aldosterone infusion did not increase mRNA 
levels of TNF-α, MCP-1 or CD68 neither in MR WT nor in EC MR KO mice (Figure 38). These data 
suggest that increased aldosterone in obesity is not involved in inducing proinflammatory 
changes in the adipose tissue. Furthermore, we conclude that an endothelial MR deletion has no 
effect on the pro-inflammatory state of the WAT. 
 
Figure 38. The expression level of proinflammatory gene products is not altered in the WAT by 
aldosterone and/or endothelial MR ablation. mRNA levels of epididymal fat pad in vehicle- or 
aldosterone-infused MR WT and EC MR KO mice were standardized to S12 and normalized to ND levels for 
CD68, TNF-α, MCP-1. Data are mean±SEM; n=6-8.*P<0.05 for MR WT ND vs MR WT HFD; #P<0.05 for EC 
MR KO ND vs EC MR KO HFD. 
  
5 Results 
 
 
- 82 - 
 
5.3.3 Endothelial MR ablation diminishes aldosterone-induced 
expression of endothelial prostanoids- and ROS-modulating 
enzymes 
In a next step, we investigated which obesity-induced pro-inflammatory, vasoconstricting or 
pro-oxidative mediators were directly enhanced by aldosterone or the endothelial MR in aortic 
endothelial cells. To do so, we isolated fresh aortic endothelial cells from MR WT and EC MR KO 
mice, infused with aldosterone for 2 weeks. 
Concerning inflammatory changes, we could not detect ICAM-1 and VCAM-1 mRNA expression 
by qPCR measurements (data not shown); C1-inhibitor mRNA was expressed, but unaltered in 
all conditions (Figure 39A). Interestingly, we observed a decrease in MR mRNA in EC MR KO 
mice, suggesting a successful ablation of the MR in aortic endothelial cells (Figure 39A). Testing 
the expression of mediators that are involved in the development of endothelial dysfunction 
showed that prostacyclin synthase mRNA expression is significantly enhanced by exogenous 
aldosterone, independent of the endothelial MR (Figure 39B). On the other hand, aldosterone-
induced COX-1 mRNA expression was significantly decreased in EC MR KO mice (Figure 39B). 
COX-2 and eNOS mRNA expression were not significantly altered by aldosterone or endothelial 
MR KO (Figure 39B). 
Taken together, exogenous aldosterone alone did not induce expression of proinflammatory 
mediators in aortic endothelial cells. In contrast, aldosterone seems to induce prostacyclin 
expression in an endothelial MR-independent manner and influence COX-1 expression in an 
endothelial MR-dependent manner.  
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Figure 39. Aldosterone-induced changes are partially attenuated by MR antagonism in aortic 
endothelial cells. Aortic endothelial cell mRNA levels in MR WT and EC MR KO mice vehicle-, or 
aldosterone-infused for 2 weeks standardized to S12 (A) C1-inhibitor, MR, (B) prostacyclin-synthase, 
COX-1, COX-2, eNOS. Data are mean±SEM; n=5-7. *P<0.05.  
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Investigations concerning enzyme systems involved in modulating oxidative stress revealed that 
mRNA expression of the antioxidant system SOD-1 inclined by aldosterone. In EC MR KO mice 
SOD-1 expression seemed to be increased again, in presence and absence of aldosterone. 
Moreover, SOD-3 mRNA was significantly decreased by aldosterone treatment. Interestingly, 
SOD-3 mRNA was also found to be attenuated in EC MR KO mice in the presence or absence of 
aldosterone (Figure 40A).  
Regarding the NADPH oxidase subunits, we found the p22phox mRNA is significantly 
upregulated by aldosterone. However, in EC MR KO mice, the expression of the subunit was 
abolished again (Figure 40B). Whereas gp91phox was unaltered in all conditions (Figure 40B), 
the mRNAs of the other NADPH oxidase subunits, namely p47phox, p40phox and Rac-1, as well 
as the antioxidant system catalase could not be detected by qPCR (data not shown). 
Taken together, aldosterone seems to alter the expression of mediators involved in the 
generation of ROS and prostanoids in an endothelial MR-dependent manner. By doing this, 
aldosterone contributes to the development of endothelial dysfunction, at least in part, via MR 
signaling. 
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Figure 40. Aldosterone-induced oxidative stress-related changes are attenuated by MR antagonism 
in aortic endothelial cells. Aortic endothelial cell mRNA levels in MR WT and EC MR KO mice vehicle- or 
aldosterone-infused for 2 weeks standardized to S12 (A) SOD-1, SOD-3, (B) p22phox, gp91phox. Data are 
mean±SEM; n=5-7. *P<0.05.  
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6 Discussion 
The data obtained in this PhD thesis contribute to the understanding of the role of aldosterone in 
obesity-induced endothelial dysfunction and evaluate for the first time in vivo the role of the 
endothelial MR in this context. Our experimental study provided three major findings:  
 Diet-induced obesity increases proinflammatory cytokines in the WAT and enhances 
expression of mediators involved in generation of oxidative stress as well as in 
generation of vasoconstricting prostanoids in aortic endothelial cells. Thereby, obesity 
induces endothelial dysfunction.  
 
 Pharmacological inhibition of the MR diminishes these changes. It attenuates 
proinflammatory cytokine expression in the WAT, tips the balance of pro-oxidative 
parameters in aortic endothelial cells towards the anti-oxidative side and induced the 
expression of eNOS. These beneficial changes reverse obesity-induced endothelial 
dysfunction. 
 
 
 Deletion of endothelial MR is sufficient to protect from harmful effects induced by 
obesity or exogenous aldosterone in the aorta: Endothelial MR deletion diminishes 
aldosterone-induced effects in aortic endothelial cells, tips expression of ROS-regulating 
enzymes towards endothelial protection and abolishes thereby aldosterone-induced 
endothelial dysfunction.  
 
 Prostanoids appear to play a dominant role in obesity and aldosterone-induced 
endothelial dysfunction based on the strong impact HFD, aldosterone infusion and 
endothelial MR knock-out have on endothelial COX-1 and prostacyclin synthase mRNA 
expression and the fact that COX-inhibition by indomethacin reverts aldosterone-
induced endothelial dysfunction. 
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6.1 Pharmacological MR antagonism in diet-induced obese 
mice 
6.1.1 Metabolic changes 
In order to characterize the effects of endogenous aldosterone in obesity on the development of 
endothelial dysfunction, we analyzed metabolic, inflammatory and vascular changes in diet-
induced obese mice. We observed an increase in relative body weight gain in all obese mice, 
independent of MR antagonism. Therefore, we suggest that MR signaling is not affecting body 
weight. These findings are in line with a recent report investigating the effects of MR antagonism 
in genetically obese mice219. 
In addition to that, we showed that pharmacological blockade of MR in obese mice attenuates 
hyperglycemia and improves glucose tolerance. Indeed, MR antagonism has been reported to 
reduce insulin resistance in genetically obese mice216,219.  Aldosterone impairs insulin-induced 
glucose uptake by two ways: first by decreasing the expression of glucose transports in the 
skeletal muscle and in the liver224 and second, by degrading the IRS-1 and -2 in cultured 
adipocytes225. These effects may account for skeletal, hepatic and adipocyte insulin resistance in 
obesity and diabetes.  
6.1.2. RAAS-related changes 
We demonstrated that plasma aldosterone concentration is increased in diet-induced obese 
mice. This observation has been also been reported previously200-201 but it remains unclear why 
aldosterone is increased during weight gain. Obesity-induced systemic RAAS activation seems 
unlikely, since we and others202,288 observed no change in renin plasma concentration or activity 
in obesity. Activation of a local adipose RAAS, contributing to the increased aldosterone 
production, can be ruled out, since adipocytes are not expressing aldosterone synthase208. In 
addition, adipose tissue derived- AngII is unable to enhance aldosterone secretion in 
adrenocortical cells208.  
RAS-independent factors have been demonstrated to stimulate aldosterone secretion in obesity. 
The oxidized derivative of linoleic acid EKODE, which is increased in obesity, stimulates 
aldosterone secretion in adrenocortical cells directly206-207. Moreover, the increased release of so 
far unidentified aldosterone-releasing factors by the WAT in obesity stimulates aldosterone 
production209. Interestingly, classical adipokines such as IL-6, TNF-α, and leptin can be excluded 
as direct stimuli of adrenal steroidogensis208. This suggests that not the systemic or local adipose 
RAS induces the aldosterone production in obesity, but rather the WAT itself, in its function as 
fat storage organ and as endocrine organ, plays a crucial role in the increased aldosterogenesis. 
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The increased aldosterone levels in obesity might play an important role in inducing endothelial 
dysfunction and inflammation in this context.  
Besides from the elevated plasma aldosterone levels in obesity, we could show that increase in 
aldosterone is even more pronounced when EPL is administered. This is in line with a previous 
publication showing that MR antagonism increases plasma aldosterone levels in genetically 
obese mice219. The increase in plasma aldosterone after EPL treatment implies that the blockade 
of MR is efficient and, due to a missing negative feedback loop, enhances aldosterone release.  
Surprisingly, we did not observe an increased urinary aldosterone level, in high fat diet-obese 
mice, unlike shown by others219 in genetically obese (db/db) mice. There might be several 
explanations for this observation. One could be that aldosterone degrading reductases might be 
more active in obese mice leading to shorter half-life of aldosterone in the circulation. This 
possibility is however not likely in view of the lack of increase in urinary corticosterone 
metabolites shown in Figure 22B (same reductases). Another explanation might be that obesity 
blunts the circardian variations of aldosterone production and favours a rather continuous 
aldosterone level. This would explain the relatively high aldosterone levels measured in the 
plasma of high fat diet-obese mice at a time, when endogenous aldosterone is very low in mice 
maintained under normal diet (mice were sacrificed 4h after beginning of the light period) and 
the rather low 24h averaged urine aldosterone levels.  
Apart from increased plasma aldosterone levels in obesity, we observed a non-significant 
increase in MR mRNA expression in aortae and WAT of obese C57BL/6. So far, only one study by 
Hirata216 shows an increased MR mRNA expression in adipocytes from genetically obese mice. 
They propose that enhanced MR expression is due to increased ROS levels in the WAT216 and 
suggest that the emerging oxidative stress might induce the expression of adipose MR that 
further augments fat ROS production and inflammation of adipose tissue. Since we do not 
observe a significant MR regulation in the adipose tissue of obesity, we rather suggest that 
aldosterone and not oxidative stress is responsible for MR activation in our mouse model of diet-
induced obesity.  
6.1.3 White adipose tissue inflammation 
Obesity alters genes expression and induces inflammation in the WAT of genetically obese 
mice289 similar to the changes reported in humans55,290. Along that line, we observed an 
increased expression of MCP-1, TNF-α and macrophage marker CD68 in the obese epididymal, 
mesenteric and periadventitial WAT.  
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This study as well as others216,219 could show that EPL decreases mRNA of obesity- and 
inflammation-related changes such as MCP-1 and TNF-α mRNA expression as well as 
macrophage infiltration in the epididymal, mesenteric and periadventitial WAT, suggesting that 
obesity is associated with an activated MR. Indeed, the MR has been shown to regulate 
transcription through inhibition of AP-1/NFκB protein–DNA complexes291 that  can influence the 
expression of proinflammatory adipokines like TNF-α, IL-1β, IL-6 and leptin219,292-294. Since 
obesity-associated proinflammatory changes in the WAT such as TNF-α and MCP-1 can 
contribute to the development of insulin resistance27,295, we propose that decreased expression 
of adipokines by MR antagonism participates in the improved glucose tolerance in our mouse 
model of diet-induced obesity. These findings highlight the positive effects of MR blockade on 
adipocyte dysfunction and insulin resistance. 
6.1.4 Endothelial dysfunction 
Obesity, insulin resistance and hypertension enhance endothelial dysfunction296. We could 
confirm these findings in obese mice and provide mechanistic insight by demonstrating that MR 
antagonism prevented endothelial dysfunction. This beneficial effect of MR antagonism might be 
either explained by indirect beneficial effects of EPL on the WAT, concerning inflammation and 
insulin resistance, or by direct EPL effects on the arterial vascular cells.  
The indirect EPL-induced vascular protection in obesity could be due to 2 different beneficial 
actions of MR antagonism: First, due to restored glucose tolerance upon EPL treatment, since 
acute hyperglycemia reduces NO bioviability in the vasculature and enhances endothelial 
dysfunction297-298. Second, it could be explained by the decreased expression of adipokines in the 
WAT upon EPL treatment, since WAT-derived cytokines can contribute directly to the 
development of endothelial dysfunction299-301. In addition, type 2 diabetes has been shown to be 
associated with increased TNF-α, MCP-1, and IL-1b signaling, which exacerbates inflammation 
as well as superoxide production by NADPH oxidase in the vessel, thereby leading to endothelial 
dysfunction302-304.  Thus, both the ameliorated glucose tolerance as well as diminished adipokine 
expression upon EPL treatment might be responsible for restored endothelial function in 
obesity.  
On the other hand, there is accumulating evidence suggesting that the unfavorable effects of 
aldosterone on vascular function arise from a direct aldosterone-induced vasculopathy 
characterized by decreased NO and increased oxidative stress: aldosterone attenuates 
endothelial NO bioactivity via MR activation171,305 and induces superoxide production via NADPH 
oxidase induction with further degradation of endogenous NO171,240,250,306. Moreover, aldosterone 
increases the expression of COX-2266 and induces vascular inflammation307. These latter finding 
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would imply that aldosterone induces endothelial dysfunction directly via activation of MR in 
endothelial cells. 
6.1.5 Aortic endothelial cell expression pattern 
Endothelial cells line the luminal wall of the vessel and are therefore in direct contact with the 
circulating blood and the underlying vascular layers. Thus, they are in perfect position to receive 
signals from the circulation and mediate them to the vasculature. Since we could show profound 
metabolic changes in obesity, associated with increased plasma aldosterone levels and distinct 
MR-induced endothelial dysfunction, we decided to characterize the mRNA expression levels in 
isolated aortic endothelial cells. Intensive literature research revealed the lack of an efficient and 
quick methodology to isolate fresh aortic endothelial cells to investigate the direct effects of diet-
feeding or hormone-administration on aortic endothelial cell expression. In turn, we decided to 
establish such an isolation protocol by ourselves, allowing us to characterize the influence of 
obesity and MR antagonism on aortic endothelial mRNA expression. 
6.1.5.1 Inflammatory changes  
In vascular inflammation, endothelial cells are characterized by the expression of various 
inflammatory genes such as ICAM-1, and VCAM-1151. Both are transmembrane cell adhesion 
molecules, involved in the adhesion and transmigration of leukocytes and monocytes into the 
tissue308-310. We could show that obesity induces the expression of VCAM-1 and ICAM-1 in aortic 
endothelial cells. In contrast, MR antagonism has no influence on VCAM-1 expression, whereby 
ICAM-1 expression is significantly attenuated by EPL.  
It has been reported that ICAM-1 is regulated in response to oxidative stress and 
proinflammatory cytokines as IL1- , TNF-α and IL-6311-313. Therefore, the beneficial effects of 
MR antagonism in obesity on ICAM-1 expression might be due to the attenuated expression of 
WAT-derived adipokines upon EPL treatment. In contrast to that, Caprio and colleagues170 
showed that aldosterone activates endogenous MR in cultured human coronary endothelial cells 
and promotes gene ICAM-1 expression and leukocyte adhesion. Since they used an considerable 
higher aldosterone concentration (3604.4ng/l) to induce aldosterone effects then we observe in 
the plasma of obese mice (416.7(±38.03)ng/l), we suggest that the MR-dependent ICAM-1 
induction, observed by Caprio170, might be due to the non-physiological aldosterone 
concentration.  
On the other hand, various adipokines, secreted by the WAT, induce activation and inflammation 
in endothelial cells22. We could show that EPL attenuates MCP-1 and TNF-α expression in the 
WAT in obesity. Therefore, we suggest that the beneficial effects of MR antagonism on 
inflammatory molecules in aortic endothelial cells in obesity might be attributed to the EPL-
induced advantageous regulation of adipokines in the WAT.  
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In obesity, the classic pathway of the complement system that is part of the innate immune 
system is massively activated in insulin resistant adipocytes314. The complement system consists 
of a number of proteins in the blood that circulated in an inactive precursor state. When 
stimulated by one of several triggers such as inflammation or infection, proteases in the system 
cleave specific proteins to release cytokines and initiate an amplifying cascade of further 
cleavages. The net result of this activation cascade is a potentiation of the response and 
activation of a cell-killing membrane attack complex315. The protease C1-inhibitor acts on the 
components of complement system and prevents its spontaneous activation. Also, the C1-
inhibitor suppresses the influx of leukocytes to the site of inflammation by decreasing the 
vascular permeability316. A beneficial action C1-inhibitor has been demonstrated in several 
inflammatory diseases as endotoxin shock317 and myocardial ischemia reperfusion injury318. In 
addition to the regulation of cell adhesion molecules, we proved that the C1-inhibitor of the 
complement system is beneficially regulated upon EPL treatment in obesity. We suggest that the 
attenuated inflammation in obesity by MR antagonism allows the expression of C1-inhibitor that 
contributes to anti-inflammatory changes in the circulation.  
6.1.5.2 ROS-related changes  
ROS are key triggers of inflammation319. Their vascular levels are determined by the rate of 
superoxide production and degradation, depending on the expression and proper function of 
numerous enzymes involved in ROS handling by the cell. Systemic oxidative stress is known to 
be increased in obesity320.  Along this line, we identified a pro-oxidative mRNA expression 
pattern in aortic endothelial cells obtained from obese mice, which may contribute to 
endothelial dysfunction. In terms of ROS scavenging enzyme systems, we detected attenuated 
levels of SOD-1 and SOD-3 in obese mice. This is in line with observations that obesity is 
associated with a decreased expression of SOD-3 in the WAT and the plasma80. Interestingly, we 
could show enhanced expression of these antioxidant enzymes upon EPL administration. 
Regarding ROS-generating enzymes, an increasing body of evidence suggests that the 
endothelial gp91phox-containing NADPH oxidase isoform (NOX2) is the most important 
superoxide anion source in the vascular wall321. Indeed, increased activity of NOX2 makes an 
important contribution to the pathogenesis of experimental models of vascular diseases 
cholesterol-induced atherosclerosis and hypertension322-323. Along that line, we showed that 
obesity enhances the expression of the NOX2 subunits p40phox and Rac-1. Interestingly, MR 
antagonism exerts beneficial down regulating effects not only on these two subunits, but also on 
p22phox, p47phox, and p40phox. 
In summary, we observed a pronounced pro-oxidative mRNA expression pattern in aortic 
endothelial cells in obesity which was attenuated by MR antagonism. Therefore, some of these 
obesity-induced changes might be induced by the increased aldosterone in obesity. 
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6.1.5.3 Prostanoids and eNOS-related changes  
The vascular expression of the prostanoids producing enzymes COX-1 and COX-2 is enhanced in 
various animal models of hypertension, diabetes and obesity, contributing to a pronounced 
endothelium-dependent vasoconstriction133,324-328. In hypertension, COX-1 co-localizes with 
prostacyclin synthase and induces the generation of prostacyclin60. This prostanoid is the major 
endothelium-derived contracting factor in the hypertensive rat aorta and mediates endothelial 
dysfunction325,329-330. In contrast, prostacyclin plays no major role in diabetes-associated 
endothelial dysfunction331. Instead, prostaglandin has been shown to be more important in 
carrying out vasoconstrictor actions in diabetic arteries331. Nevertheless, it is still not completely 
clear, which COX-derived prostanoids are the key players in obesity-induced endothelial 
dysfunction332.  
In agreement with the literature, mRNA analyses of endothelial cells revealed that obesity 
increases the expression of enzymes involved in prostanoid generation, such as COX-1 and 
prostacyclin synthase. Interestingly, pharmacological MR antagonism is not influencing any of 
these enzymes. Therefore, we propose that enhanced expression of prostanoid-producing 
enzymes in obesity is triggered by other stimuli than aldosterone-induced MR signaling. In 
hypercholesterolemia, COX-1 promotes vascular inflammation and thrombogenesis333. Since EPL 
is not changing plasma cholesterol levels in obesity235, we suggest that high cholesterol levels 
are mainly responsible for enhanced COX-1 expression in obesity. 
NO, generated by eNOS, plays an important role in vascular homeostasis, adhesion of 
inflammatory cells and function of platelets334. Three major factors may account for decreased 
NO levels, leading to endothelial dysfunction. First, functional abnormalities of the NO-synthase 
due to enzyme substrate or cofactor deficiency335-336; Second, decreased bioavailability of NO by 
oxidative stress337 and third, reduced expression of eNOS. Several publications suggest that 
inflammation and expression of proinflammatory cytokines attenuate eNOS expression in 
endothelial cells in the vasculature338-340. Considering these three possibilities, we suggest that 
the non-significant increase in eNOS expression in aortic endothelial cells of obese mice might 
lead to an increased NO content in the aorta. Such an enhanced NO production in endothelial 
inflammation has been already described by others341. Since we showed an increased expression 
of NAPDH oxidase subunits in obesity as well, this might lead to an enhanced production of 
harmful peroxynitrite contributing to the generation of endothelial dysfunction in obesity. 
Additionally, we could show that EPL further enhances eNOS expression in endothelial cells. 
This might be due to anti-inflammatory changes associated with MR antagonism that increase 
eNOS expression. Since several NADPH oxidase subunits are decreased by EPL, oxidative stress 
might be attenuated and therefore NO bioavailability increased by MR antagonism. These 
changes might contribute to the restored endothelial function in obesity. 
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6.1.6 Conclusion 
We could demonstrate that endothelial dysfunction in obesity correlates with impaired glucose 
tolerance and a proinflammatory expression profile in the white adipose tissue as well as in 
endothelial cells. The aortic endothelium in obesity is characterized by increased expression of 
proinflammatory adhesion molecules, NADPH oxidase subunits, prostanoid-generating enzymes 
and decreased antioxidant systems. Pharmacological MR blockade by EPL abolishes obesity-
induced impaired glucose tolerance, WAT inflammation and endothelial activation. In aortic 
endothelial cells, pharmacological MR antagonism results in decreased expression of NADPH 
oxidase subunits as well as in enhanced expression of antioxidant systems and eNOS. 
Prostanoid-generating enzymes remain unaltered by EPL. Taken together, all advantageous 
effects, induced by MR antagonism in obesity, contribute to a beneficial modulation of 
endothelial mRNA expression, protecting the endothelium form dysfunctionality (Figure 41). 
 
 
Figure 41. Obesity-induced endothelial dysfunction is restored by MR antagonism. EPL provides 
beneficial effects on glucose tolerance, inflammation and expression of ROS-generating enzymes, thereby 
diminishing endothelial dysfunction.  
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6.2 Endothelial MR ablation in obese or aldosterone-infused 
mice 
6.2.1 Metabolic changes 
In order to determine the role of the endothelial MR in the context of high endogenous (obesity) 
or high exogenous aldosterone-induced endothelial dysfunction we analyzed metabolic, 
inflammatory and vascular changes of obese or aldosterone-infused EC MR KO mice, 
respectively. We could show that a deficient endothelial MR signaling is not affecting weight or 
impairing glucose tolerance in obesity, ruling out an important role of the endothelial MR in the 
context of weight gain control or development of impaired glucose tolerance. 
6.2.2 RAAS-related changes 
In obese mice, we observed that plasma aldosterone levels are increased, in the presence or 
absence of the endothelial MR. Thus; endothelial MR-induced signaling pathways are not 
affecting the enhanced aldosterone secretion obesity. To characterize the role of increased 
aldosterone without obesity in detail, we infused lean MR WT and EC MR KO mice with 
exogenous aldosterone for 2 weeks. In order to mimic the aldosterone levels in obesity we 
infused 50 μg/kg/d aldosterone, resulting in an aldosterone plasma concentration of 
413.5±36.01 ng/l. This is comparable to the plasma aldosterone concentration of obese C57BL/6 
(416.7±38.03 ng/l) and allowed us to study the role of aldosterone, independent of metabolic 
and inflammatory changes, associated with obesity. Since aldosterone was released by the 
osmotic minipumps without any circadian alterations, aldosterone-induced effects might be 
stronger in aldosterone-treated mice than in obese mice with endogenously increased 
aldosterone. 
Unlike measured in obese C57BL/6 mice (Figure 23), no increase in tissue MR expression was 
observed in obese EC MR KO mice and their corresponding WT littermates. Since the increase in 
MR expression is not pronounced in obese C57BL/6 either, the change in tissue MR expression is 
in our mouse model of diet-induced obesity is likely negligible. 
6.2.3 White adipose tissue inflammation 
White adipose tissue contains multiple cells including preadipocytes, adipocytes, small blood 
vessels, and macrophages. Cross-talk between the different adipose tissue cell types, in 
particular between macrophages, preadipocytes, and adipocytes, is thought to be an important 
factor for promoting a proinflammatory state in obesity30,342. Especially macrophages are 
important cytokine-secreting cells in the obese WAT54. As also shown by others289 we observed 
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that obesity induces a pronounced inflammation in the WAT of mice. In addition, we 
demonstrated that expression of MCP-1, TNF-α as well as of macrophage marker CD68, is 
induced to the same extent in obese EC MR KO and MR WT mice, suggesting that endothelial MR 
signaling is not affecting inflammation in the obese WAT. 
Recently, it has been demonstrated that a conditional MR ablation in myeloid cells, that are 
macrophage progenitor cells, attenuates MCP-1 release in macrophages and diminishes overall 
inflammation in cerebral ischemia343. Along this line, we observed both, a successful endothelial 
MR ablation and an additional MR deletion in macrophages isolated from EC MR KO mice. As the 
obesity-induced inflammation in the WAT of EC MR KO mice remains unaltered compared with 
MR WT mice, we propose that the impact of the unspecific MR ablation in macrophages is 
negligible in our setting.  
Aldosterone has been reported in vitro to increase the expression of MCP-1, TNF-α, and IL-6 in 
cultured preadipocytes219. In contrast, we showed in vivo that an exogenous aldosterone infusion 
does not enhance the expression of TNF-α, MCP-1 or macrophage accumulation in the WAT. This 
observation might due to the expression of 11β-HSD1 in the WAT tissue17. Since 11β-HSD1 
determines intracellular glucocorticoid levels by regenerating cortisol from cortisone173, the MR 
in the adipose tissue is likely to be more activated by cortisol than by aldosterone217, even if 
aldosterone levels are increased. Furthermore, activity and expression of 11β-HSD1 are known 
to be increased in obese WAT212-213 and are associated with the development of metabolic 
syndrome214-215,344. Accordingly, it is proposed that in obesity it is the increased intracellular 
level of glucocorticoids rather than of aldosterone that triggers MR-induced adipocyte 
inflammation. 
6.2.4 Endothelial function 
As described above, MR antagonism restores obesity-induced endothelial dysfunction 
completely. To elucidate the role of the endothelial MR in this context, we analyzed EC MR KO 
mice with regard to endothelial function. As we did not observe any impact of endothelial MR 
ablation on body weight, glucose tolerance, or adipose inflammation in obesity, we were able to 
elucidate the role of the endothelial MR independent, of other factors favoring endothelial 
dysfunction.  
In the course of our experiments, we could emphasize the central role of the MR in endothelial 
cells: Deletion of the endothelial MR is sufficient to abolish obesity-induced as well as 
aldosterone-induced endothelial dysfunction. Consequently, the endothelial MR is critical for 
endothelial dysfunction in obesity. 
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Considering our observation that expressions of COX-1 and prostacyclin synthase are increased 
in aortic endothelial cells in obesity, we assessed the role of COX in aldosterone-induced 
endothelial dysfunction by using the COX-inhibitor indomethacin. Interestingly, we could show 
that COX-blockade restores endothelial function, underlining the importance of prostanoids in 
obesity- and aldosterone-induced endothelial dysfunction. The role of prostanoids in 
aldosterone-induced endothelial function has been described in hypertensive and normotensive 
rats239. Furthermore, Traupe and collegues328 demonstrated that obesity induces endothelial 
dysfunction in a COX-1 dependent manner and enhances the expression of the vascular TP. 
These changes induce vasoconstriction in obesity.  
Taken together, these results suggest that the endothelial MR as well as vasoconstrictor 
prostanoids contribute to both obesity- and aldosterone-induced endothelial dysfunction.  
6.2.5 Aortic endothelial cell expression pattern 
The previous observations, allowed us to characterize the influence of a pharmacological MR 
blockade on aortic endothelial cells in obesity - reflecting a state of endogenous aldosterone 
elevation. To further characterize, which ones of these changes are mediated via the endothelial 
MR, we analyzed aortic endothelial cells of EC MR KO and MR WT mice treated with exogenous 
aldosterone. Our data revealed changes concerning ROS-producing and -degrading enzyme 
systems, as well as concerning enzymes, involved in the generation of vasoconstrictor 
prostanoids. 
6.2.5.1 Inflammatory changes  
We observed endogenous expression of ICAM-1 and VCAM-1 in lean C57BL/6 mice, and an 
increased endothelial activation in obesity. Interestingly, exogenous aldosterone administration 
alone – in the absence of obesity – is not sufficient to increase expression of adhesion molecules. 
Thus, we conclude that aldosterone is not inducing these obesity-associated proinflammatory 
changes in aortic endothelial cells.  
6.2.5.2 ROS-related changes  
We showed that obesity is associated with a suppressed expression of SOD-1 and SOD-3. 
Interestingly, we observed a similar expression profile of these antioxidant systems upon 
aldosterone administration. Whereas MR antagonism restores the expression of both enzymes 
in obesity, endothelial MR ablation in aldosterone-treated mice ameliorates only the expression 
of SOD-1. Thus, in obesity, aldosterone decreases SOD-1 expression in an endothelial MR-
dependent manner. In contrast, both endogenous (obesity) as well as exogenous aldosterone 
seem to attenuate SOD-3 expression, independently of the endothelial MR in aortic endothelial 
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cells. The enhanced SOD-3 expression in obesity upon MR antagonism might be due to 
endothelial MR independent anti-inflammatory effects of EPL in obesity. 
Moreover, we could demonstrate an advantageous decrease of NADPH oxidase subunit 
expression in obesity upon MR antagonism. It has been demonstrated in the literature, that 
aldosterone increases the aortic expression of p22phox, gp91phox, p47phox and Rac-1253-254,345. 
Along that line, we could show that p22phox is regulated by aldosterone in an endothelial MR-
dependent manner. Interestingly, p22phox is induced by exogenous aldosterone but not by 
obesity. This might be due to the fact that the endogenous aldosterone is released in a circadian 
rhythm, whereas exogenous aldosterone is administered by constant infusion, having a greater 
impact on the endothelial MR. Nevertheless, the attenuated p22phox expression upon EPL in 
obesity might be due to blocked endothelial MR signaling.  
Since we demonstrated that only p22phox is regulated by exogenous aldosterone endothelial 
MR-dependently, we presume that all other subunits of the NADPH oxidase, modulated by 
obesity and MR antagonism, are regulated by EC MR-independent pathways.  
Taken together, we observed that aldosterone decreases both SOD-1 as well as SOD-3 and 
enhances p22phox expression in aortic endothelial cells. Of note, only SOD-1 and p22phox are 
regulated in similar directions by MR antagonism and endothelial MR ablation, respectively. 
Thus, we propose that these two mediators are modulated by the endothelial MR in obesity and 
are key factors in the generation of oxidative stress in this setting. 
6.2.5.3 Prostanoids related changes  
We demonstrated that aldosterone induces COX-1 and prostacyclin synthase expression in 
aortic endothelial cells. Our findings are in agreement with the literature346-347 and match our 
organ chamber experiments.  
Interestingly, COX-1 expression is induced by aldosterone in an endothelial MR-dependent 
manner, whereas MR antagonism does not prevent obesity-induced COX-1 increase. We suggest 
that the endothelial MR plays an important role in inducing COX-1 expression when aldosterone 
is chronically increased by exogenous administration. In obesity, in contrast, other factors 
besides elevated aldosterone participate to the induction of COX-1 mRNA, in particular also 
hypercholesterolemia333. Prostacyclin is a potent vasoconstrictor and plays a major role in 
aldosterone-induced endothelial dysfunction in normotensive and hypertensive conditions346-
347. Along that line, we could demonstrate that aldosterone induces prostacyclin synthase 
expression in an endothelial MR-independent manner. Taken together, we showed that in 
obesity, aldosterone is of minor importance in inducing COX-1 expression, whereas aldosterone 
is responsible for prostacyclin synthase induction in an endothelial MR independent manner. 
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Concerning eNOS expression, we did not observe any expression changes upon aldosterone 
treatment. We suggest, that eNOS is not regulated by aldosterone directly.  
6.2.6 Conclusions 
In conclusion, our work with genetically ablated MR in endothelial cells identifies the endothelial 
MR as a crucial mediator in obesity- and aldosterone-induced endothelial dysfunction. 
Prostanoids play an important role in the development of endothelial dysfunction in this 
pathophysiological setting, since COX-inhibition restores aldosterone-induced endothelial 
dysfunction. In fact, aldosterone enhances expression of COX-1 in an endothelial MR-dependent 
way and prostacyclin synthase expression in an endothelial MR-independent way. Nevertheless, 
endothelial MR-induced COX-1 activation seems to be of minor importance in obese mice; in 
contrast, aldosterone-induced prostacyclin synthase expression could be responsible for 
increased prostacyclin levels in obesity. Furthermore, aldosterone modulates NADPH oxidase 
subunit p22phox and SOD-1 in a MR-dependent manner. Thus, endothelial MR signaling in 
obesity plays a critical role in generation of oxidative stress. 
Taken together, we propose that in obesity, endogenous aldosterone enhances production of 
prostanoids. The endothelial MR-mediated alterations concerning ROS-producing enzymes 
might be crucial in the generation of endothelial dysfunction (Figure 42). 
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Figure 42. Aldosterone-induced endothelial dysfunction is restored by endothelial MR deletion. 
Endothelial MR ablation provides beneficial effects on ROS-and prostanoids-generating enzymes, thereby 
diminishing endothelial dysfunction. 
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6.3 Summary: Aldosterone effects in obesity-induced 
endothelial dysfunction 
In this thesis, we could show that aldosterone and the endothelial MR play an important role in 
the development of obesity-induced endothelial dysfunction. 
Obesity is associated with impaired glucose tolerance as well as adipose tissue inflammation. 
Moreover, obesity has a profound influence on aortic endothelial cell expression concerning 
inflammatory molecules, antioxidant systems, NADPH oxidase and enzymes involved in the 
generation of prostanoids. All of these effects contribute to the generation of endothelial 
dysfunction. Interestingly, MR antagonism attenuates most of the factors favoring endothelial 
dysfunction and induces the expression of eNOS. Only obesity-induced expression of COX-1 and 
prostacyclin synthase is not beneficially influenced by MR antagonism. Nevertheless, the 
advantageous effects of MR antagonism are sufficient to restore obesity-induced endothelial 
dysfunction. 
Analyses of mice lacking the endothelial MR revealed that endothelial MR ablation restores 
obesity- as well as aldosterone-induced endothelial dysfunction, without affecting glucose 
tolerance or white adipose tissue inflammation. Interestingly, we could show that aldosterone 
induces expression of the NADPH oxidase subunit p22phox and decreases expression of the 
antioxidant system SOD-1 in a MR-dependent manner in aortic endothelial cells. This might 
increase oxidative stress that contributes to endothelial dysfunction. 
Both aldosterone and obesity induce COX-1 expression in aortic endothelial cells. MR 
antagonism does not alter COX-1 expression in obesity, whereas MR ablation in endothelial cells 
ameliorates aldosterone-induced COX-1 expression. We presume that besides endothelial MR-
mediated COX-1 induction, COX-1 expression in obesity can be induced by other 
pathophysiological changes such as hypercholesterolemia. Endothelial MR-induced COX-1 
expression might be of minor importance in obesity. Prostacyclin synthase expression is 
increased both in obesity as well as upon exogenous aldosterone administration, either. Since 
the increased prostacyclin synthase is not affected by EPL or endothelial MR ablation, we 
propose this enzyme to be induced by aldosterone in an endothelial MR-independent manner. 
Altogether, we identified the following factors to be involved in obesity-induced endothelial 
dysfunction. First, endogenous aldosterone in obesity enhances oxidative stress by altering ROS-
related proteins via the endothelial MR. Second, endogenous aldosterone in obesity regulates 
prostacyclin synthase expression in an endothelial MR-independent manner. Third, obesity 
enhances expression of COX-1 via an endothelial MR-independent mechanism and, of minor 
importance, via an endothelial MR-dependent mechanism (Figure 43). 
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The endothelial MR plays a central role in regulating the expression of NADPH oxidase subunit 
p22phox and antioxidant SOD-1. Indeed, a beneficial regulation of theses enzymes in obesity tips 
the balance to the anti-oxidative side, resulting in attenuated endothelial dysfunction. 
 
 
 
Figure 43. Mechanisms of aldosterone-induced endothelial dysfunction in obesity. 
Pathophysiological changes in obesity contribute to endothelial function and are not mediated 
via the endothelial MR, but can be blocked by EPL ( ). Some of the aldosterone-induced 
changes contributing to endothelial dysfunction are mediated via the endothelial MR ( ) and 
others independently of the endothelial MR ( ). 
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The expression of ROS- and prostanoid-generating enzymes is increased in obesity and 
contributes to endothelial dysfunction. The question rises how the endothelial MR-dependent 
oxidative stress is key player in obesity-induced endothelial dysfunction. 
First, endothelial MR-mediated changes in oxidative stress might directly damage endothelial 
cells348 by decreasing the content of vasodilating NO in the vasulature111.  
Second, ROS and prostanoids are able to induce each other’s expression, promoting a viscous 
cycle that enhances endothelial dysfunction in obesity. On one side, COX-derived prostanoids 
can enhance generation of ROS in the endothelium and thereby impair endothelium-dependent 
contraction349. On the other side, ROS activate COX and induce prostacyclin production in 
cultured endothelial cells350. This positive feedback loop in endothelial cells could lead to an 
amplification of prostanoid production and to increased oxidative stress in endothelial cells. 
Moreover, increased extracellular oxidative stress, due to increased endothelial NADPH oxidase, 
can induce vasoconstriction as it does in hypertension by acting on COX in smooth muscle 
cells351. Along that line, ROS induce VSMC contraction by stimulating Ca2+ release from the 
sarcoplasmatic reticulum352 and ameliorates the stability of the prostanoid receptors at the cell 
membrane of VSMCs in vitro353-354. This is in line with the observation, that TP expression is 
increased in atherosclerotic lesions in mice and humans355-356. 
Taken together, the increase in oxidative stress as well as the increase of prostanoids production 
in aortic endothelial cells might lead to a vicious circle, in which the harmful effects of these 
mediators amplify each other, thereby enhancing the progression of endothelial dysfunction. 
The increased expression of p22phox in obesity mediated by the endothelial MR- might be one 
of the crucial mediators that tips the balance in the generation of endothelial dysfunction in 
obesity. 
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6.4 Future directions 
6.4.1 Eplerenone - a potent anti-inflammatory molecule 
Many studies, including our own, demonstrate that MR blockade exhibits anti-inflammatory 
properties in the animal model219,234-235. These studies propose MR antagonism as a promising 
tool for treating obesity-associated inflammatory diseases such as endothelial dysfunction and 
type 2 diabetes. 
While the treatment of endothelial dysfunction in obesity appears reasonable and safe, 
treatment of type 2 diabetes, the most common cause of chronic kidney failure357, needs to be 
approached with caution. Kidney failure may favor hyperkalemia, given the central role of the 
kidney and aldosterone in plasma potassium homeostasis. Thus, MR blockade has to be used 
carefully in chronic kidney disease given the increased risk of hyperkalemia. 
6.4.2 Targeting the endothelial MR - a new strategy to treat obesity-
induced endothelial dysfunction and vascular disease 
The present thesis demonstrates for the first time that endothelial MR plays a crucial role in 
obesity-induced endothelial dysfunction. Therefore, the endothelial MR could be an interesting 
pharmacological target to treat endothelial dysfunction, impaired glucose tolerance, and pro-
inflammatory changes in obese patients without significant kidney disease.  
Whereas we could show that aldosterone induces prostacyclin synthase in an endothelial MR-
independent manner, COX-1 regulation in obesity remains to be clarified. COX-1 expression was 
unaltered in obesity upon EPL treatment, and abolished in aldosterone-treated mice, when the 
endothelial MR was ablated. To characterize the role of the endothelial MR in this context 
further, aortic endothelial cell analyses of obese EC MR KO mice would be of interest. Such 
analyses disclose the endothelial MR-dependent pathways in obesity in more detail and are the 
missing puzzle in our characterization of aortic endothelial cells. Along that line, it would be 
appealing to investigate if a selective COX-1 or prostacyclin synthase inhibition is sufficient to 
restore obesity- or aldosterone-induced-endothelial dysfunction.  
Since we could show a profound impact of obesity and aldosterone on enzyme systems involved 
in ROS- as well as prostanoid-generation, measuring the actual content of ROS and prostanoids 
in the vasculature of the different mice seems to be interesting. 
One limitation of our study is that our data do not allow us to conclude whether the protective 
effects concerning endothelial function seen in EC MR KO mice are exclusively due to an 
endothelial MR ablation. As reported above, adipose tissue macrophages and T cells are the main 
cytokine-secreting cells in the white adipose tissue in obesity 55. Of note, we observed no 
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changes in proinflammatory expression pattern in the WAT of obese EC MR KO mice compared 
with EC MR WT mice. Thus, partial ablation of the MR in adipose tissue macrophages may play a 
minor role in the context of obesity-induced endothelial dysfunction. Nevertheless, future 
studies with a more specific endothelial cell promoter to ablate the MR, using the CreLoxP 
system would be meaningful. 
We were able to show that the endothelial MR plays a crucial role in endothelial dysfunction, 
being the initial step of atherogenesis. In addition to the growing evidence related to the 
protective effects of the MR antagonists in the metabolic syndrome, our results highlight the 
importance of the relationship between aldosterone and endothelial MR in the development of 
this disease. 
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ACE  angiotensin-converting-enzyme 
Ach  acetylcholine 
ACTH  adrenocorticotropic hormone 
AngI  angiotensin I 
AngII  Angiotensin II 
AP-1  activator protein-1 
ARB  angiotensin-receptor blockers 
ARF  aldosterone-releasing factor 
AT1  type I AngII receptor 
AT2  type II AngII receptor 
BAT  brown adipose tissue 
BH4  4-tetrahdrobiopterin 
bp  base pairs 
BSA  bovine serum albumine 
C1-inhibitor inhibitor of the complement factor 1 
CaCl2  calcium chloride 
CD86  macrophage glycoprotein 
cGMP  cyclic guanosin monophosphate 
CNS  central nervous system 
COX-1  cyclooxygenase-1 
8 Abbrevations 
 
 
- 109 - 
 
COX-2  cyclooxygenase-2 
CREM  cyclic AMP-response element modulator 
CRP  C-reactive protein 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
EC MR KO MRflox//Tie2Cre 
EDCF  Endothelium-derived contracting factors 
EDRF  endothelium-derived relaxing factors 
EKODE  12,13-epoxy-9-keto-10(trans)-octadecenoicacid 
ENaC  amiloride-sensitive epithelial sodium channel 
eNOS  endothelial nitric oxide synthase  
EPL  eplerenone 
FFA  free fatty acids 
FITC  fluoresceinisothiocyanat 
fwd  forward 
G6P-DH  glucose-6-phosphate dehydrogenase 
GC  guanylylcyclase 
GLUT  glucose transporter 
GR  glucocorticoid receptor 
Hbb-b1 hemoglobin, beta adult major chain   
HFD  high-fat diet 
HFD EPL high-fat diet containing eplerenone 
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ICAM-1 intercellular adhesion molecule-1 
IL  interleukin 
IP  prostacyclin receptor 
IP3  inositol 1,4,5-trisphosphate 
IRS  insulin receptor substrate 
JNK  c-Jun N-terminal kinases 
KCl  kalium chloride 
KO  knockout 
LDL  low-density lipoprotein 
LOX-1  oxidized LDL receptor 
MCP-1  monocyte chemoattractant protein-1 
MgCl2  magnesium chloride 
min  minutes 
MMP  matrix metalloproteinase 
MR  mineralocorticoid receptor 
mRNA  messenger ribonucleic acid 
MR WT  MRflox/WT  
NaCl  natrium chloride 
NADPH nicotinamide adenine dinucleotide phosphate-oxidase 
NaHCO3 sodium bicarbonate 
NaH2PO4 sodium phosphate 
Na2SO4  sodium sulfate 
ND  normal diet 
NE  norepinephrine 
Nedd4  neuronal precursor cell expressed developmentally downregulated 4 
nedd4-2 nedd4 isoform 2 
NF-kB  nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
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NO  nitric oxide 
NOS  NO synthase 
NOX  NADPH oxidase 
ONOO٠- peroxynitrit 
PAI-1  plasminogen activator inhibitor-1 
PBS  phosphate buffered saline 
PGE2  prostaglandin E2 
PGD2  prostaglandin D2 
PGH2  prostaglandine 
PGI2  prostacyclin 
PLA2  phospholipase 2 
PKG  cGMP-dependent protein kinases 
PPAR-y peroxisome proliferator-activated receptor-y 
RAAS  renin-angiotensin-aldosterone-system 
ROS  reactive oxygen species 
rev  reverse 
rpm   rounds per minute 
RT-PCR real time reverse transcription polymerase chain reaction 
sec  seconds 
SEM  standard error of the mean 
sGC  soluble guanylatecyclase 
SGK1  serum-and glucocorticoid-induced kinase 1 
SNP  sodium nitroprussid 
SOD  superoxide dismutases 
SRE  steroid response element 
TLCK  Nα-Tosyl-L-lysinchlormethylketon - Hydrochlorid  
TNF-α  tumor necrosis factor-α 
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TP  prostanoid receptor/ thromboxane receptor 
TXA2  thromboxane 
U  Units 
VCAM-1 vascular cell adhesion protein-1 
VSMC  vascular smooth muscle cells 
vWF  von Willebrandt-factor 
WAT  white adipose tissue 
11β-HSD 11β-hydroxysteroid dehydrogenase 
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